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Vitiligo is a common depigmenting skin disorder with devastating psychological implications.  
Although evidence strongly suggests that melanocytes die in various forms of vitiligo, it is also 
evident, at least in certain cases, that melanocytes/melanoblasts survive in an undifferentiated stem 
cell form and it is from these that re-pigmentation is assumed to occur.  Treatment of this 
distressing condition remains ‘hit-or-miss’ and patients’ responses are unpredictable.  This study 
aims to integrate prognostic variables such as the molecular profile of vitiliginous lesions and the 
patient’s epidemiological profile, to develop a reliable and sensitive prognostic test enabling 
clinicians to plan an individualized, rational therapeutic approach for their vitiligo patients.  The 
analysis of tyrosinase and TRP-2 mRNA expression in vitiliginous skin using quantitative RT-
qPCR revealed the presence of melanoblasts/melanocytes in 60% of patients (n=21).  When this 
survival was calculated as a percentage of the mRNA expression in the pigmented positive control 
specimen, it was found to range from 4% to 46% survival.  Patients were subsequently treated with 
either potent topical corticosteroid ointment or 5% khellin cream in combination with daily sunlight 
exposure for 3 months and their clinical response was then assessed and correlated to the lesional 
melanocyte status.  A good response (>50% repigmentation) was found in 3/5 patients 
demonstrating both tyrosinase and TRP-2 gene expression, in only 1/4 patients demonstrating TRP-
2 gene expression alone and in 0/3 patients demonstrating only tyrosinase gene expression.  The 
presence of both tyrosinase and TRP-2 mRNA expression is therefore a significant positive 
prognostic indicator.  A significant correlation (R
2 
=0.8919) was found between melanocyte 
survival and response to khellin therapy suggesting that therapeutic modalities stimulating 
melanocyte proliferation and migration should be employed in patients demonstrating a melanocyte/ 
melanoblast reservoir.  Conversely, an absence of melanocyte/melanoblast markers is predictive of 
a poor response to treatment with 7/9 patients lacking lesional tyrosinase or TRP-2 mRNA 
expression demonstrating <25% repigmentation at the conclusion of the 3 month treatment period. 
Therapeutic options such as surgery or cosmetic camouflage techniques should be considered for 
these patients.  The epidemiological profile was not found to be a significant prognostic factor in 













1. CHAPTER 1: 
 
1.1 A VIGNETTE 
 
Mrs H. is an eighty-two year old woman who was first seen in 1995 at the Groote Schuur Hospital 
PUVA clinic.  She presented with a short history of depigmented skin lesions predominantly on her 
trunk and limbs and also had a background history of rheumatoid arthritis.  She had been a widow 
for fifteen years and it was noted at the initial consultation that she seemed depressed.  A diagnosis 
of vitiligo was made and various treatments including potent corticosteroids and PUVA were 

































She demonstrated no response to therapy and her areas of depigmentation continued to  
expand, despite a minipulse of oral corticosteroids.  It was noted that the patient was  















Fig 2.  Photographs of Mrs H. taken on 19/01/96 
 
One year after starting treatment, she confessed to suicidal ideation and she was urgently referred to 
psychiatry where Imipramine 175mg nocte and Alprazolam 0.25mg bd were commenced.  Three 
months later, after sixty-five treatments of PUVA (an accumulative dose of 468.5) and a second 
minipulse of corticosteroids, a remarkable burst of repigmentation was seen.  She met and fell in 

































Fig 3.  Photographs on Mrs H. taken on 04/04/96 
 
In September 2000, following the sudden and devastating deaths of a close friend, her sister and her 


























Despite continuing with the PUVA treatments, she continued to depigment.  This was exacerbated 














Fig 5.  Photographs of Mrs H. taken on 27/09/01  
 
In 2001, following review by the psychiatrists, her antidepressant medication was adjusted and it 
was decided to continue with her PUVA therapy despite her high accumulative dose of 2910 (visit 













































Fig 6.  Photographs of Mrs H. taken on 04/04/02 
 
Her clinical course continued to fluctuate with her mental state until in July 2004, it was decided to 
stop her therapy due to her increasing fragility and age.   
 
This case demonstrates the devastating psychological implications of vitiligo and the striking 
correlation between the patient’s mental state and her response to therapy.  It provokes a question as 
to whether the impact of the state of mind on a patient’s therapeutic course has been 
underestimated.  The negative impact of vitiligo on the patient’s quality of life and mental well-
being can be exacerbated by treatment failure.  A prognostic test to identify those patients likely to 
be good candidates for therapy and those who are unlikely to respond would avoid the despondency 















The melanocyte is a neural crest-derived cell that migrates via the mesenchyme into the epidermis 
and hair follicles during embryogenesis (Li and Urmacher, 2007).  The immediate unpigmented 
precursors of melanocytes are called melanoblasts.  Other sites of melanocyte migration include the 
uveal tract of the eye, the leptomeninges and the inner ear (Tobin, 2006).  As can be seen in Figure 
7, melanocytes can be found in both the basal layer of the hair matrix where they actively produce 
melanin as well as in the outer root sheath where they remain amelanotic (Tobin and Bystryn, 
































Melanocytes can be identified within the fetal epidermis by immunohistochemical staining as early 
as 50 days of gestation.  By electron microscopy, melanin-containing melanosomes can be seen 
during the fourth month of gestation (Li and Urmacher, 2007).  During embryogenesis, melanin-
producing melanocytes can also be found diffusely throughout the dermis, appearing initially at ten 
weeks of gestation in the head and neck region (Holbrook et al., 1989).  By birth, however, active 
dermal melanocytes remain only in the anatomic sites of the head and neck, the dorsal aspects of the 
distal extremities and the presacral area (Sagebiel and Odland, 1972).  In the epidermis, 
melanocytes reside within the basal layer but their dendrites come into contact with keratinocytes as 
far away as the mid stratum spinosum (Figure 2).  The epidermal melanin unit describes this 


































1.2.2 Melanosome Formation 
 
The melanosome is a unique organelle within the cytoplasm of the melanocyte which protects the 
melanocyte from melanin precursors (e.g. phenols, quinines) which can lead to lipid peroxidation.  
The melanosome contains both proteins regulating melanin biosynthesis as well as matrix proteins 
which form a scaffold upon which the melanin is deposited (Orlow, 1995).  Several of the enzymes 
involved in melanogenesis undergo glycosylation and processing within the endoplasmic reticulum 
and Golgi apparatus and are then packaged into vesicles after which they combine with the matrix 
proteins (Thody, 1995).  Melanosome formation can be divided into four stages from stage I where 
the melanosome is spherical and amelanotic to stage IV where the melanosome is oval with a heavy 
deposition of melanin.  This process is under tight regulation and stimulated by environmental 
changes such as exposure to ultraviolet light.  As melanin is deposited within the melanosome, it 
migrates via microtubules and by means of kinesin and dynein proteins into the dendrites (Hara et 
al., 2000).  The melanosomes are then transferred to the neighbouring keratinocytes, either within 
the epidermis or within the anagen hair matrix (Seiberg et al., 2000).  They form supranuclear caps 
over the keratinocyte nuclei in order to protect the nuclear DNA against solar ultraviolet radiation 
(UVR) (Jimbow et al., 1992).  Normal skin colour is determined predominantly by melanocyte 
activity and not by their density.  Melanocyte activity relates to the number of melanized 
melanosomes produced as well as the efficiency of their transfer to the neighbouring keratinocytes.  
Lightly pigmented skin has fewer and mainly stage II and III melanosomes whereas darkly 
pigmented skin contains a greater number of primarily stage IV melanosomes (Kadekaro et al., 
2003). 
 
1.2.3 Melanogenesis and Melanin 
 
There are three types of melanin in mammals:  brown, slightly soluble, intermediate molecular 
weight (MW) eumelanin, black, insoluble, high MW eumelanin and the reddish-yellow alkali-
soluble, low MW phaeomelanin (Jimbow et al., 1976). 
The synthesis of melanin can be divided into the following steps (Figure 3): 
1.)  The hydroxylation of L-tyrosine to L-dopa by the tyrosinase enzyme 
2.)  The oxidation of L-dopa to dopaquinone by tyrosinase – this is the precursor for both 
eu/pheomelanins and is the limiting step in melanogenesis 











Both eu/pheomelanogenesis require the oxidation of dopa to dopaquinone.  Thereafter, the 
conversion of dopaquinone to leuko-dopachrome signals eumelanin production, while the addition 
of cysteine to dopaquinone to yield cysteinyldopa occurs in pheomelanin production (Kobayashi et 
al., 1995).  In oculocutaneous albinism type 1A where there are mutations in both copies of the 
tyrosinase gene and thus complete loss of enzyme activity, the hair, skin and eyes contain no 
melanin pigment.  In oculocutaneous albinism type 1B, however, where there is decreased enzyme 
activity, pheomelanin is produced (leading to the now obsolete term of ‘yellow mutants’) (Mange et 
al., 2000).  As less tyrosinase activity is required for pheomelanogenesis compared to 



































Melanins are group of complex polymers which function to camouflage as well as to quench the 
oxidative free radicals generated via exposure to UVR.  The type and amount of melanin production 
is a complex interplay of the various melanogenic enzymes’ activities as well as the activity of 
proteins such as tyrosinase-related protein 1(TRP-1) which stabilize the activity of tyrosinase and 
the P protein.  Several factors regulate the activity of these key melanogenic proteins including 
melanocyte stimulating hormone (MSH), basic fibroblast growth factor (bFGF), endothelin-1 and 














1.2.4 Melanogenic Proteins 
 
 
The key regulatory and rate-limiting enzyme in the melanogenic pathway is tyrosinase which 
controls tyrosine hydroxylation, the initial biochemical reaction in this pathway.  This is the rate-
limiting step as the remainder of the pathway can proceed spontaneously at physiological pH 
(Hearing et al., 1991).  Tyrosinase also catalyzes the additional steps of dopa oxidation as well as 
the oxidation of 5,6-dihydroxyindole to indole-5,6-quinone.  Dopachrome tautomerase, also known 
as tyrosinase-related protein 2 (TRP-2) because of the similarity of its amino acid sequence to 
tyrosinase, converts dopachrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) ( Fang et al., 
2001).  Another melanogenic protein, tyrosinase-related protein 1 (TRP-1) is involved in the 
stabilization of tyrosinase (Del Marmol et al., 1993).  A fourth transmembrane protein, P protein, is 
involved in the transport of small molecules across the melanosome membrane and regulates the 
processing and trafficking of tyrosinase, possibly via the control of pH or glutathione content within 
intracellular compartments (Abdel-Malek et al., 1993).   Two of the melanogenic proteins pertinent 




Tyrosinase is a copper requiring metalloenzyme with two putative copper-binding sites and is 
regarded as the rate-limiting enzyme for the melanin biosynthetic pathway described above.  Thus, 
in patients with Menkes kinky hair disease which is characterized by a dysfunctional 
transmembrane copper-transporting ATPase, there is hypopigmentation of the hair.  The human 
tyrosinase gene has been mapped to chromosome 11(q14-q21) and is comprised of five exons and 
four introns spanning a distance of over 65 kb (Giebel et al., 1991).  This type I membrane 
glycoprotein is synthesized as a nascent 60-kDa polypeptide which then undergoes glycosylation in 
the endoplasmic reticulum (ER) to produce a 70-kDa polypeptide (Halaban et al., 2000).  This 
glycosylation of tyrosinase is imperative for its translocation to premelanosomes (Imokawa et al., 
1982).  It is then targeted to the Golgi apparatus where it undergoes further modifications forming 
the 80-kDa mature wild-type (WT) isoform.  The mature tyrosinase enzyme then proceeds to the 












Hydroquinone, used as a depigmenting agent in the treatment of melasma is a competitive inhibitor 
of tyrosinase activity (Bolognia and Pawelek, 1988).  Another competitive inhibitor is L-
phenylalanine and in phenylketonuria where there is a defect in the enzyme L-phenylalanine 
hydroxylase converting L-phenylalanine to L-tyrosine resulting in elevated levels of L-
phenylalanine, a diffuse pigmentary dilution is evident (Bolognia and Pawelek, 1988). 
 
1.2.4.2 Tyrosinase-Related Protein 2 
 
Original descriptions of the melanogenic pathway reported tyrosinase as the only involved enzyme 
due to the fact that in vitro, L-dopa can spontaneously oxidize to form melanin.  However, by the 
late 1970s, the role of TRP-1 was recognized and 1984 saw a breakthrough in the recognition of a 
new enzyme which catalyses the conversion of dopachrome to 5,6-dihydroxyindole-2-carboxylic 
acid by means of a keto-enolic tautomerization.  This enzyme was thus initially named dopachrome 
tautomerase and later, due to its sequence homology to tyrosinase, it was called tyrosinase-related 
protein 2.  It has been mapped to chromosome 13q32 (Yokoyama et al., 1994).  Steel et al., (1992) 
developed a probe derived from TRP-2 and were able to detect migratory melanoblasts following 
their emergence from the neural crest as early as 10 days post coitum in mice.  This enzyme is 
therefore thought to be the earliest known melanocyte-specific marker capable of detecting even 





Vitiligo is a common depigmenting skin disorder that affects approximately 1% of the world’s 
population and often has devastating psychological implications. The word ‘vitiligo’ has its origins 
from the Latin word ‘vitulum’ meaning ‘small blemish’ (Nordlund and Ortonne, 1998) and is 
characterised by well-circumscribed, irregularly shaped, white cutaneous macules (Ortonne, 2008).  
This leukoderma is due to the loss or decrease of functional pigment-producing melanocytes from 
otherwise healthy looking skin (Jimbow, 1998).  This disorder is classified according to its extent 
and distribution into generalised and localised forms.  The generalised form may be termed vitiligo 
vulgaris, where symmetrical, scattered macules involve the whole body or vitiligo universalis in 
which there is > 80% depigmentation.  The localised form may be focal or may be termed 











2005).  There have been no reports on the prevalence of vitiligo in South Africa, but dermatologists 
report on high numbers of patients seeking therapy for this disfiguring disorder. 
 
1.3.1 Aetiopathogenesis of Vitiligo 
 
Although there are numerous theories regarding the pathogenesis of vitiligo, the cause remains 
unknown.   The numerous clinical manifestations of the disorder suggest a multifactorial interplay 
of factors leading to melanocyte destruction.   
 
Pigment cell research on the biology of melanocytes and melanogenesis during the 1960s and 1970s 
resulted in the development of three general theories regarding the aetiopathogenesis of vitiligo.  
These have subsequently been superceded by convergence theories. 
 
1.3.1.1 The Autoimmune Theory 
 
The autoimmune hypothesis proposes that melanocytes are destroyed due to alterations in humoral 
or cellular immunity. 
 
The theory of dysfunctional humoral immunity is based on the association of vitiligo with various 
autoimmune syndromes and originated in Thomas Addison’s report of the association of adrenal 
failure with vitiligo in 1855.  The incidence of vitiligo is 10-15 times greater in patients with 
autoimmune disease, with 30% of patients being affected with at least one additional autoimmune 
disorder.  Furthermore, these autoimmune diseases occurred at an increased frequency in the first-
degree relatives of vitiligo patients.  Similarly, in multiplex generalised vitiligo families, higher 
frequencies of psoriasis, rheumatoid arthritis and type I diabetes mellitus were noted in addition to 
autoimmune thyroid disease, Addisons’s disease, systemic lupus erythematous and pernicious 
anaemia (Rezaei et al., 2007).  It has also been reported that vitiligo patients have an increased 
prevalence of autoantibodies to endocrine organs without manifesting clinical disease (Auer-
Grumbach and Stangl, 1993).   
 
The most significant advance in promotion of this theory was the demonstration of specific 
antibodies to melanocyte cell-surface antigens present in the blood circulation of vitiligo patients.  











candidiasis but were felt to be a non-specific marker of immune dysregulation (Nordlund et al., 
1981).  Naughton et al., (1983) published the first report to document convincingly the presence of 
antimelanocyte antibodies in vitiligo patients by means of immunoprecipitation.  In further studies 
(Naughton et al., 1986), they found that the antibody levels were elevated more in actively 
progressing vitiligo as well as in patients with co-morbid autoimmune diseases.  Further evidence of 
these antimelanocyte antibodies were provided by indirect immunofluorescence studies (Bystryn 
and Naughton, 1985), immunoblotting, enzyme-linked immunoabsorbent assays (ELISA) (Harning 
et al., 1991; Baharav et al., 1996) and by means of passive transfer experiments (Gilhar et al., 1995; 
Kemp et al., 1997; Kemp et al., 1998).  In 1988, Norris et al., proved the functional significance of 
these autoantibodies by demonstrating that sera from vitiligo patients were cytotoxic for 
melanocytes both by complement lysis and by antibody-dependent cell-mediated cytotoxicity.  The 
significance of these autoantibodies in vitiligo, however, is controversial.  Some researchers have 
proposed that these antibodies are formed secondary to primary melanocyte destruction by other 
mechanisms (Halaban and Moellmann, 1993).  The identification of antibodies to tyrosinase, an 
intracellular antigen, in 61% of patients with vitiligo suggests that the contents of a damaged 
melanocyte are released into the circulation, initiating an immune response (Song et al., 1994).  
Autoantibodies directed against TRP-1 and TRP-2 as well as against two transcription factors SOX9 
and SOX10 and the melanin-concentrating hormone receptor-1 have also been identified (Kemp et 
al., 1998).  Other authors propose that these antibodies are the markers of vitiligo rather than the 
cause of it.  The role of humoral immunity in vitiligo is further supported by a study demonstrating 
the destruction of melanocytes from normal skin engrafted on to nude mice injected with vitiligo 
patient sera (Ongenae et al., 2003). 
 
Cellular immunity has also been strongly implicated in the pathogenesis of vitiligo (Palermo et al., 
2001).  T cells infiltrating perilesional epidermis are mostly CD8
+
 T cells expressing the cutaneous 
lymphocyte-associated antigen (CLA) skin homing receptor.  These cells are concentrated in the 
vicinity of disappearing melanocytes and express perforin and granzyme B suggesting that they play 
a role in melanocyte destruction.  In addition, skin-homing, melanocyte-specific cytotoxic T 
lymphocytes (CTLs) have been found in the peripheral blood of vitiligo patients demonstrating 
specific cytotoxic responses against Melan-A/MART-1, tyrosinase and gp100.  The presence of 
these CTLs has also been shown to be related to disease activity.  These findings support the 
hypothesis of vitiligo being a CD8
+ 













Several immunogenetic factors predisposing patients to autoimmune disorders have been associated 
with vitiligo, adding credence to the theory that the disease may have an autoimmune component 
(Passeron and Ortonne, 2005).  An association between major histocompatibility complex (MHC) 
class II human leucocyte antigen (HLA) alleles and vitiligo, particularly HLA-DR4 has been found.  
Other studies have revealed an association between vitiligo and HLA-DRB1*03, HLA-DRB1*04 
and HLA-DRB1*07 alleles in Turkish patients (Tastan et al., 2004) and with HLA-DRB4*0101 and 
HLA-DRBa*0303 alleles in Dutch patients (Venneker et al., 1993).  An association between several 
genes involved in antigen presentation including the TAP-1 gene has also been found (Zhang et al., 
2005). 
 
Other factors such as an increased expression of intercellular adhesion molecule-1 (ICAM-1) 
involved in antigen presentation by perilesional melanocytes as well as the repigmentation of 
patients with immunosuppressive agents such as corticosteroids provide further support for the 
autoimmune hypothesis (Van den Wijngaard et al., 2000).  An increased vulnerability to attack by 
complement due to an aberrant expression of membrane regulators of complement activation 
including decay acceleration factor and membrane cofactor protein in lesional melanocytes and 
keratinocytes has also been cited as contributing to the abnormal cellular immune responses against 
pigment cells (Van den Wijngaard et al., 2002). 
 
1.3.1.2 The Neural Hypothesis 
 
The neural hypothesis advocates that a neural dysfunction is responsible for the depigmentation 
seen in vitiligo and was initially based on anecdotal observations that stress may precipitate vitiligo.  
This hypothesis also rests on the feeble embryological fact that both melanocytes and neural cells 
are derived from the neural crest and that both cells types use the amino acid tyrosine for their 
major end products namely melanin and catechols respectively.  The distribution of segmental 
vitiligo lesions in a quasi-dermatomal distribution has also been used as a validating fact (Nordlund 
and Ortonne, 1998).  In addition, mild degenerative changes shown in a small proportion of axons 
and Schwann cells of nerves supplying vitiliginous lesions have been hypothesised to disturb the 
function of the melanocytes in these lesions (Al’Abadie et al., 1995).  Hara et al., (1996) propose 
that these degenerative changes lead to an increase in neurotransmitters released from the nerve-











dysfunction of the cholinergic sympathetic nerves and increased adrenergic tone in the affected skin 
(Wu et al., 2000).  The discovery of the role of neuropeptides in melanocyte differentiation 
(dendricity) and in melanogenesis boosts this hypothesis.  An increased immunoreactivity of 
neuropeptide Y as well as an altered balance of nerve growth factor receptors and calcitonin gene-
related peptide has also been seen in vitiligo skin.  In addition, vitiligo skin has been shown to have 
increased catechol-o–ethyltransferase and monoamino oxidase activities and an increased 
expression of β2-adrenoreceptors which has been hypothesised to induce melanocyte dysfunction 
and injury by promoting the production of melanocytotoxic compounds and be decreasing the anti-
oxidant capacities of melanocytes.  Apart from this direct cytotoxic effect, these catecholamines 
could also cause indirect damage by activating α-receptors of skin arterioles leading to severe 
vasoconstriction.  Severe or repeated hypoxic attacks lead to the production of toxic ROS resulting 
in depigmentation (Hsin-Su, 2002).  Currently, however, the role of the nervous system in vitiligo, 
if any, is ill-defined. 
 
1.3.1.3 The Autocytotoxic Hypothesis 
 
The self-destruction hypothesis describes a toxin-mediated impairment of melanocytes suggesting 
that the leukoderma in vitiligo results from melanocyte destruction by toxic intermediates of 
melanin.  It hypothesises that tyrosine analogues and intermediates including DOPA, DOPAchrome 
and 5,6-dihydroxyindole in melanin synthesis are toxic to melanocytes.  Melanocytes have a 
protective mechanism leading to the successful elimination of toxic intermediates.  Any disruption 
of this process leads to toxin accumulation, free radical generation and melanocyte destruction.  
This theory was first proposed due to the observation that hyperpigmented skin including 
periorificial skin seemed to be more susceptible to vitiligo than lighter skin (Lerner, 1971).  The 
theory was further supported by the chemical leukoderma induced by hydroquinone derivatives like 
monobenzone which have been proposed to disrupt melanogenesis leading to the excessive 
production or leakage of toxic intermediates into the cytoplasm of the melanocyte and subsequent 
cytolysis (Cummings and Nordlund, 1995). 
 
1.3.1.4 The Genetic Hypothesis 
 
Both family and twin studies implicate genetic susceptibility to vitiligo.  These studies indicate that 











incomplete penetrance rather than by simple Mendelian genetics. No clear association of vitiligo 
with any particular genetic locus has been found (Majumder et al., 1993).  A number of candidate 
genes for vitiligo including AIS1, AIS2, AIS3 and PTPN22 however, have been proposed.  In 
addition, several genome-wide linkage analyses have been performed by Spritz et al., (2007) and 
mutations in the NALP1, a gene on chromosome 17p has been found.  This vitiligo susceptibility 
gene encodes SLEV1, a protein identified in families with vitiligo-related systemic lupus 
erythematosus and is a component of inflammasomes which regulate the activity of caspases.  
 
1.3.1.5 The Oxidative Stress Theory 
 
Schallreuter and Pittelkow, (1991) described a complex biochemical imbalance between 
keratinocytes and melanocytes resulting in an impaired anti-oxidant capacity as well as an increase 
in the levels or reactive oxygen species (ROS) in vitiligo patients.  They demonstrated that 
keratinocytes cultured from vitiliginous skin had a low catalase activity resulting in an increase in 
hydrogen peroxide which in turn inhibited tyrosinase activity.  Such high levels of epidermal 
hydrogen peroxide have been confirmed in vivo by non-inv sive Fourier transform Raman 
spectroscopy of vitiligo skin.  They also described an increased calcium uptake in these cultured 
keratinocytes leading to an inhibition of the activity of the thioredoxin reductase antioxidant 
(Schallreuter and Pittelkow, 1988).  Other studies corroborating this theory showed a decrease in 
other anti-oxidants such as vitamin E, glutathione and total ubiquinone in vitiligo patients compared 
to healthy controls (Passi et al., 1998; Maresca et al., 1997).  Red blood cells and peripheral 
lymphocytes as well as melanocytes in vitiligo patients have been shown to have an altered 
antioxidant pattern (decreased catalase and glutathione peroxidase activity, increased superoxide 
dismutase and xanthine oxidase activity) associated with increased lipid peroxidation (as 
demonstrated by a high level of malonylmaldehyde and decreased membrane polyunsaturated fatty 
acids) (Dell’Anna et al., 2001; Agrawal et al., 2004).  The consequences of this elevated ROS 
production include oxidation of DNA bases and peroxidation of both intracellular and cytoplasmic 
membranes (Giovanelli et al., 2004).  This in turn can result in cell membrane damage with loss or 














1.3.1.6 Reduced Melanocyte Survival 
 
It has been proposed that the reduced melanocyte survival seen in vitiligo patients occurs as a result 
of a deficiency of factors imperative for their maintenance (Kitamura et al., 2004).  The stem cell 
factor (SCF)/KIT/microphthalmia-associated transcription factor (MITF)/Bcl-2 pathway, in 
particular, has been implicated.  Vitiligo keratinocytes have been shown to have a lower expression 
of keratinocyte-derived factors including SCF and MITF-M protein expression within the peri-
lesional epidermis has been shown to be downregulated.  This suggests that a dysfunction of the 
SCF/KIT/MITF survival pathway within melanocytes leads to apoptosis. 
 
1.3.1.7 Transepidermal Melanocytorrhagy 
 
A chronic detachment and transepidermal loss of melanocytes in patients with generalised vitiligo 
has recently been described in an in vivo study (Gauthier et al., 2003).  This study theorises that 
mechanical stress leads to the detachment of melanocytes followed by a process of elimination via a 
passive transepidermal migration.  This theory is supported by the observations of vitiligo occurring 
more frequently in sites predisposed to friction or excessive movement including the hands, knees 
and below the bra strap. 
 
1.3.1.8 The Convergence Theory 
 
The convergence theory (illustrated in Figure 10) reconciles the genetic, immune-mediated, auto-
cytotoxic and neuronal hypotheses (Le Poole and Boissy, 1997; Passeron and Ortonne, 2005; Taieb, 
2000).  In 2005, a study by Le Poole et al., proposed a temporal sequence between the immune-
mediated and toxic-mediated damage to melanocytes.  They suggested that an immune response in 
the form of a specific cytotoxic T-cell reaction is mounted due to primitive intrinsic damage of the 
melanocytes resulting in the first evidence of depigmentation.  In vitro evidence of this intrinsic 
‘fragility’ of the melanocytes was provided by reports of a genetic polymorphism resulting in an 
elevated production of toxic intermediates such as 6- and 7-BH4 (6- and 7- tetrahydrobiopterin) 
damaging the fragile melanocytes.  These compounds lead to an inhibition of the antioxidant 
enzymes and of melanin synthesis as well as to an increased production of catecholamines with a 











activate dendritic cells with the resulting dendritic cell effector functions playing a role in the 
melanocyte destruction (Hsin-Su, 2002).    
 
It is also imperative to note that other studies have focused on the role of keratinocytes and 
Langerhans cells in vitiligo.  It has been noted that the keratinocytes in adjacent normal-appearing 
skin as well as perilesional skin are abnormal with cytoplasmic vacuolization and extracellular 
granular material can also be seen indicating keratinocyte damage (Moellmann et al., 1982).  
Degenerative changes and functional impairment have also been observed in Langerhans cells.  
This suggests that the entire keratinocyte-Langerhans cell-melanocyte unit is affected in vitiligo.  
An important study conducted by Bondanza et al., (2007) suggests that vitiligo may be a disorder 
primarily of keratinocytes resulting in melanocyte damage.  They found that almost all involved 
keratinocytes in vitiligo patients had a decreased life span in vitro compared to uninvolved 
keratinocytes.  They also found that they were unable to maintain melanocytes in culture in a 













Fig 10.  Summary of the convergence theory.  Growth factors, ROS, antibodies, cytokines, T cells 
and inflammatory mediators combine to produce melanocyte destruction.  Exogenous influences 
including ultraviolet light radiation (UVR), neural stimulation and cytotoxic lymphocytes and 
antibodies converge to influence melanocyte viability. (ET-1 = endothelin-1; βFGF = basic 
fibroblast growth factor; NGF = nerve growth factor; SCF = stem cell factor; TGF-α= transforming 






































1.3.2 Melanocyte Survival in Vitiligo and Repigmentation 
 
The fundamental question of what exactly is happening to the melanocytes in vitiligo remains 
unresolved.  Although evidence strongly suggests that melanocytes die in various forms of vitiligo, 
it is also evident, at least in certain cases, that melanocytes survive in an undifferentiated stem cell 
form and it is from these that re-pigmentation can occur (Nordlund and Ortonne, 1998; Gottschalk 
and Kidson, 2007).  Husain et al., (1982) demonstrated the presence of the melanocyte-specific 
tyrosinase enzyme in vitiliginous skin using a sensitive fluorimetric method as well as by 
14
C(U)-L-
tyrosine incorporation into melanin, thus unequivocally proving survival of melanocytes in 
vitiliginous skin.  A further study confirmed that this tyrosinase enzyme was responsible for the 
enzymatic hydroxylation of tyrosine to dopa in epidermal homogenates of lesional skin.  An 
ultrastructural study conducted by Bartosik et al., (1998) observed the presence of stage III/IV 
melanosomes within basal keratinocytes even in vitiliginous lesions of long duration.  In 2000, 
Tobin et al., obtained suction blister tissue from the lesional skin of 12 vitiligo patients and 
successfully established melanocyte cultures.  In addition, light and electron microscopy were 
utilised to demonstrate the presence of pre-melanosomes in basal and supra-basal keratinocytes of 
vitiliginous skin as well as the presence of single melanocytes in lesional skin.  Lastly, a study 
conducted by Gottschalk and Kidson in 2007 utilised the sensitive molecular technique of reverse 
transcription PCR (RT-PCR) using primers for tyrosinase and dopachrome tautomerase followed by 
Southern blotting to provide evidence of melanocyte survival in the lesional skin of 25% of vitiligo 
patients(n=12).   
 
This issue of melanocyte survival is complicated by the presence of melanocyte stem cells in the 
‘niche’ of the hair follicle.  Stem cells are defined as cells that can generate mature cells through 
differentiation as well as maintaining themselves through self-renewal (Ohyama, 2007).  It is known 
that melanoblasts from the neural crest destined for the hair follicle can be divided into two 
populations:  differentiated melanocytes localised in the hair matrix region that are responsible for 
hair colour; and melanocyte stem cells (MSC) which can be found at the lower permanent portion 
of the hair follicle and which are responsible for the repopulation of pigment cells in the cycling 
hair (Osawa et al., 2005).  Another subpopulation of melanocytes is located in the mid-portion of 
the hair follicle outer root sheath (the so-called ‘bulge’ region).  Melanocytes in this region are 
poorly differentiated, unpigmented and are considered to be melanocyte stem cells. Starrico (1994) 











sheath of hair follicles which could be activated by UV light.  In PUVA-treated vitiligo patients, 
islands of perifollicular repigmentation appear which then extend and coalesce to normalise 
pigmentation.  Thus, the melanocyte repopulation of lesional skin involves the activation and 
proliferation of these MSCs and their subsequent migration through the interfollicular epidermis 
(Norris et al., 1994). 
 
1.4 Therapeutic Options for Vitiligo 
 
The objective in the treatment of vitiligo patients is to reverse the depigmentation and to establish 
normal pigmentation in leukodermic macules.  A systematic literature review of vitiligo treatment 
options reveals mostly uncontrolled pilot studies and case reports, with treatments being evaluated 
mainly in the short term with few comparative trials.  The astonishingly small number of 
randomised control trials makes evaluation of treatment efficacy difficult and makes it impossible to 
name one single treatment modality as the most effective for a particular form of vitiligo. Current 
vitiligo therapies include topical and systemic corticosteroids, oral or topical psoralen plus UVA 
(PUVA) therapy, khellin plus UVA therapy (KUVA), narrow band (NB) UVB (TLO1) therapy 
(Hartmann et al., 2004), calcineurin inhibitors (Tjioe et al., 2006), topical calcipotriol, 308nm 
excimer laser, low energy (632.8nm) helium-neon laser (Lan et al., 2009), focused 
microphototherapy as well as surgical methods of repigmentation such as minigrafting or suction 
blisters (Jimbow, 1998).  Additional controversial therapies include topical pseudocatalase with 
NB-UVB and systemic antioxidant therapy.  Patients with generalised vitiligo with more than fifty 
to eighty percent body surface area involvement can opt to use depigmenting agents.  A met-
analysis of the literature concludes that class 3 gluococorticoids and UVB therapy are the most 
effective and safest therapies for localised and generalised vitiligo respectively (Njoo et al., 1999). 
 
Repigmentation with medical treatment has been shown to occur in three manners: 
 
1. Perifollicular: from the melanocyte reservoir in the outer root sheath of the hair follicle 
2. Marginal: from the adjacent normal skin 
3. Diffuse: from either spared epidermal melanocytes or from the reactivation of DOPA-












Treatment of vitiligo patients remains, on the whole, unsatisfactory.  Spontaneous repigmentation 
occurs in no more than 15% to 25% of cases.  Response is slow and the rate of response is low.  The 
paucity of information regarding melanocyte behaviour, both in the development of vitiligo lesions 
and in the process of repigmentation following an appropriate stimulus, makes the refining of 
treatment options difficult. 
 
1.4.1 Topical Corticosteroid Therapy 
 
A light and electron microscopic study of the effects of topical corticosteroid treatment in vitiligo 
was conducted in 1976.  Bleehen (1976) treated ten patients with either 0.1% betamethasone or 
0.05% clobetasol priopionate creams and placebo preparations for three months.  Biopsies taken 
from both steroid-treated and control areas were then studied histologically.  A marked repopulation 
of functional melanocytes in the repigmenting vitiliginous skin was seen.  These melanocytes were 
more dendritic and dopa-positive and contained numerous melanosomes of normal size, shape and 
melanization as compared to the control areas.  He concluded that topical corticosteroids can induce 
repigmentation of lesional skin.   
 
The mechanism of action of topical corticosteroids is hypothesised to be via their 
immunosuppressive and anti-inflammatory properties thus giving credence to the auto-immune 
hypothesis of vitiligo.  Corticosteroids exert their action by binding to glucocorticoid receptors.  
This receptor then translocates to the nucleus and forms a dimer which binds to the glucocorticoid 
response element of the promoter region of steroid-responsive genes.  The receptor also directly and 
indirectly inhibits transcription factors with central roles in the inflammatory response such as 
nuclear factor-κβ and activating protein-1.  This leads to inhibition of pro-inflammatory cytokines, 
adhesion molecules, inflammatory enzymes and growth factors such as tumour necrosis factor-α, 
granulocyte-macrophage colony-stimulating factor and several interleukins as well as intercellular 
adhesion molecule-1 and E-selectin.  The inflammatory response is thus dramatically reduced 
(Boumpas et al., 1993). 
 
Their immunosuppressive effects occur due to a number of factors.  Glucocorticosteroids induce a 
neutrophilia but lead to a reduction of these cells at inflammatory sites by means of inhibiting 
endothelial adhesion molecule expression and chemoattractants.  A decreased IL-2 production and 











and function of helper, suppressor and cytotoxic T lymphocytes.  Glucocorticoid use also leads to a 
decreased production and differentiation of the monocyte-macrophage cell lines as well as 
inhibiting the antigen presentation by dendritic cells to T lymphocytes (Nesbitt LT, 2008). 
 
The 1974 trial of Kandil, using 0.1% betamethasone 17-valerate for four months was the first 
randomised control double blind trial investigating the efficacy of topical corticosteroids in vitiligo.  
He found that 6/23 patients experienced 90-100% repigmentation while 3/23 patients showed 25-
90% repigmentation using the potent corticosteroid betamethasone.  Side effects included 
hypertrichosis and acne.  This limited efficacy of corticosteroids was confirmed by Clayton’s study, 
(1977) using the highly potent clobetasol proprionate as therapy.  This trial concluded that only 2/23 
patients showed >75% repigmentation while 10/23 patients demonstrated 15-25% repigmentation.  
He noted that all patients developed skin atrophy following eight weeks of treatment.  Another 
study conducted on Filipino vitiligo patients (n=25) had a remarkably different experience, finding 
that 88% of patients showed at least 90% repigmentation after six months of treatment with topical 
clobetasol proprionate cream (Geraldez and Gutierrez, 1987). 
 
The best controlled study to date of topical corticosteroids is that of Westerhof et al., (1999).  This 
study found that the potent topical steroid fluticasone used as monotherapy for nine months induced 
a mean repigmentation of only 9%, that UVA therapy alone led to a mean repigmentation of 8% 
while the two treatment modalities together induced a mean repigmentation of 31%.  This trial also 
documented that no steroid atrophy occurred.   
 
There have been numerous trials comparing a potent or highly potent topical steroid with other 
topical agents including topical pimecrolimus, topical tacrolimus, calcipotriol and PUVAsol.  These 
studies found a comparable degree of repigmentation between clobetasol and topical pimecrolimus 
(Coskun et al., 2005) and tacrolimus (Lepe et al., 2003).  They also found that the combination of 
topical betamethasone and calcipotriol had a higher efficacy than either agent alone (Kumaran et al., 
2006) and noted that the use of clobetasol induced better repigmentation than PUVAsol alone 
(Khalid et al., 1995).  Taken together, one can surmise that topical clobetasol used over two to six 
months repigments generalized symmetrical types of vitiligo to some degree.  A level 1a evidence 
meta-analysis proved class III corticosteroids such as betamethasone to be the most effective 
therapy for localised vitiligo with a significant pooled odds ratio for topical class III corticosteroids 











(2008), however, it is noted that the evidence for clinically meaningful repigmentation with topical 
betamethasone used over a period of four months is weak.  It is also important to note that as mid to 
super high-potency steroids are often required, side-effects such as atrophy can occur and have been 
observed in 14% of patients treated with class III corticosteroids (Frauman AG, 1996).  Irreversible 
striae have been found to develop on the legs after as little as four months of continuous treatment.  
Thus topical glucocorticoids are recommended for use on limited lesions or isolated macules.  The 
best response has been seen on thinner skinned areas such as the face while trunk and acral regions 
often prove resistant to this therapy.  A study conducted by Kumari, (1984) (n=75) utilising 
clobetasol proprionate treatment found that more than 80% of patients with vitiligo of the face and 
more than 40% of patients with vitiligo on the trunk or limbs demonstrated 90-100% 
repigmentation over a three year period.  He found that this repigmentation continued progressively 
even following the cessation of treatment. 
 
1.4.2 Topical Khellin and Ultraviolet Light Therapy 
 
Khellin (4,9 – dimethoxy – 7 - methyl – 5H - furo[3,2 - g] - [1] benzopyran – 5 – one) is a 
furanochrome produced from the seeds of the plant Ammi visnaga which is commonly found in the 
Eastern Mediterranean area and is known in Arabic as ‘khella’.  Its chemical structure resembles 
that of psoralen.  Khellin was introduced as a vasodilator for the therapy of angina pectoris in the 
mid-1940’s and 1950’s and no long-term side effects were reported.  The effectiveness of other 
treatments led to the discontinuation of the use of khellin in cardiac disease (Mandel et al., 1997).   
 
The mechanism of khellin stimulation of melanogenesis is still largely unknown.  In vitro studies 
have demonstrated that khellin stimulates mitosis as well as melanogenesis in human melanocytes 
and melanoma cells (Carlie et al., 2003).  In combination, khellin and UVA have a synergistic 
mitotic and melanogenic effect.  Khellin was consistently found to cause melanocyte proliferation 
and melanogenesis at concentrations between 0.01-0.5mM, with a peak stimulation at 0.01mM with 
250 mJcm² UVA.  Western blot, Northern blot and RT-PCR analysis showed that the increased 
melanogenic enzyme activity were not due to increases in gene expression or protein synthesis but 
rather that UVA treatment causes a significant increase in post-translational melanogenic enzyme 












Clinical studies conducted using topical khellin have produced varied results.  In 1992, Orecchia et 
al., evaluated the efficacy of topical khellin in combination with sunlight for vitiligo.  Forty-one 
vitiligo patients entered the study.  All patients were treated topically with 2% khellin dissolved in 
90% acetone and 10% propylene glycol.  As a control, 36/41 patients applied acetone-propylene 
glycol solution to lesions on the opposite side.  In the remaining five patients, lesions on one half of 
the body were not treated and were shielded from sunlight.  The therapy consisted of three 
treatments per week over a period of four months.  No significant difference was noted between the 
khellin and placebo-treated sides. 
 
In a subsequent, double-blind, vehicle controlled study using artificial UVA and a water/2-
propanol/propylene glycol gel formulation, the same group found that repigmentation (>51%) 
occurred in 11/31 khellin-UVA-treated areas compared to 2/31 vehicle-UVA-treated areas 
(Orecchia et al., 1999).  Repigmentation 26-50% occurred in 8/31 patients and 12/31 patients 
showed an 11-25% response.  Only one patient failed to respond to khellin-WPG plus UVA.  They 
concluded that the vehicle used in their previous study did not adequately facilitate the availability 
of khellin as there was an evident precipitation of khellin secondary to a rapid evaporation of the 
solvent following application to the skin. Their new, more appropriate pharmaceutical approach led 
to promising results.  Furthermore, over the six months of therapy, short-term side-effects such as 
symptomatic erythema or phototoxic reactions were not reported. 
 
Another study conducted by Procaccini et al., (1995) found khellin plus solar irradiation to be 
ineffective.  They evaluated the efficacy of KUVA in the treatment of vitiligo using 3% and 5% 
khellin in two different vehicles: an oil/water cream and a liquid vehicle 1-methyl-2-pyrrolidinone 
(PYR).  Repigmentation, estimated both clinically and photographically, was found to be similar on 
vitiligo patches treated with khellin and those treated only with the vehicle.   
 
An important pilot study was carried out in 2003 by Valkova et al., on 33 patients.  The efficacy of 
topical khellin (5% khellin in water/oil emulsion) plus UVA was compared to systemic PUVA 
therapy in terms of degree of repigmentation, side effects, duration of treatment and total UVA 
dose.  The authors concluded that topical KUVA may effectively induce repigmentation of vitiligo-
affected skin areas to a degree comparable to that achieved using systemic PUVA.  Topical KUVA 
was followed by >50% repigmentation in 43.8% of patients.  The authors re-iterated the many 











 Decreased photo-toxicity  
 Decreased carcinogenesis 
 No pigmentation of healthy skin 
 No significant systemic side-effects 
 Can safely be combined with solar irradiation without the risks of photo-toxic incidents 
 Home-based therapy 
 
This unresolved controversy regarding topical khellin efficacy and a need determined by the Groote 
Schuur Hospital Dermatology department for a safe, home-based therapy for vitiligo for many of 
their patients unable to utilise hospital based PUVA therapy, led in 1999 to a clinical trial.  (Milne 
et al., Unpublished data). A double-blind, placebo-controlled trail was conducted to assess the 
efficacy of 5% khellin in aqueous cream combined with solar radiation.  Sixty patients were 
involved in the study which ran over a 12 week period: 31 patients were given 5% khellin in 
aqueous cream and 29 patients were given aqueous cream only. Khellin was applied 30 mins prior 
to solar exposure for 15 mins daily, increasing to 30 mins over two weeks.  Significant clinical 
improvement (p<0.04) using topical khellin was seen in the facial region but all other body regions 
showed no statistical difference when compared with placebo.  The authors hypothesise that the 
face responds better than other areas as it has the highest concentration of melanocytes.  No 
systemic side effects were reported and 7/60 patients complained of only temporary cutaneous side 
effects in the treated areas: four had burning (three khellin, one placebo) and three had itching (one 
khellin, two placebo). 
 
In terms of KUVA’s safety, khellin has been found to have lower photogenotoxicity in yeast 
compared to 5-methoxypsoralen (5-MOP) used in PUVA (Morliere et al., 1988).  In comparison to 
results obtained with 5-MOP, khellin at a 100 times higher concentration, was found to be 
genetically inactive using doses of UVA for which 5-MOP was previously shown to exert 
significant genetic effects.  Morliere et al. (1988) found that khellin’s affinity for DNA is notably 
lower than that determined for psoralen derivatives:  5-MOP exhibits a 15 times higher binding 
constant and more binding sites as compared to khellin.  In addition, khellin is unable to induce 
interstrand cross-links in DNA upon UVA irradiation.  Trabalzini et al., (1990) also found an 
absence of photo-oxidation of DNA after treatment with khellin plus UVA suggesting that khellin 











activity of khellin with the Salmonella mutagenicity test.  When khellin was assayed with the 
Salmonella strain TA102, a 79% survival was demonstrated compared to only a 66% survival of the 
same strain with 8-MOP.  The authors thus concluded that khellin has a weak photomutagenic 
potential and that khellin may be safer than psoralens for clinical use.  The fact that khellin does not 
cause phototoxicity is thought to be due to the fact that khellin is neither a strong generator of 
reactive oxygen species nor a strong type 1 photodynamic sensitizer.  Pan et al., (2001) investigated 
the mode of the khellin’s photodynamic action on furanochromones.  They found that khellin is a 
more stable photosensitizer as compared to 8-methoxypsoralen (8-MOP) also used in PUVA. 
 
All the above-mentioned data support the notion of khellin’s safety as a phototherapeutic agent and 
substantiate khellin’s numerous advantages over the classical PUVA therapy. 
 
1.5 Principles of Real-Time RT-PCR 
 
Real-time RT-PCR is a quantitative technique for measuring the mRNA levels of a gene of interest 
relative to an internal control or housekeeping gene (Freem n et al., 1999).  The fundamental 
principle of PCR is the selective amplification of a specific DNA product through the action of 
DNA dependent DNA polymerase over a number of cycles of denaturing, annealing and extension 
of a specific DNA primer in the presence of free nucleotides and a polymerase enzyme.  In real-
time RT-PCR, fluorescence is measured during each cycle, greatly increasing the dynamic range of 
the reaction since the fluorescence generated is proportional to the amount of PCR product.  PCR 
products can be detected using either fluorescently labeled sequence-specific probes or fluorescent 
dyes.  The threshold cycle (CT) is the cycle at which there is a significant detectable increase in 
fluorescence i.e. the cycle at which the amplification plot crosses the threshold.  This threshold 
cycle can then be used to determine the starting level of the target gene.  Comparison of the CT 
value of the gene of interest with that of the endogenous reference gene allows the gene expression 
level of the target gene to be normalized to the amount of input cDNA.  The RNA encoding 
GAPDH is ubiquitously expressed and moderately abundant.  It is frequently used as an endogenous 
control for quantitative RT-PCR because its expression is constant at different times and after 
experimental manipulation.  Real-time RT-PCR has largely superceded methodologies such as 
semiquantitative and competitive RT-PCR which are reagent and labour intensive as well as being 
error prone due to the large number of sample manipulations involved.  It is currently the most 












The qPCR method used in this study involves detection of the binding of the fluorescent SYBR 
Green dye to DNA.  The SYBR Green dye exhibits fluorescence only when bound to double-
stranded DNA during the elongation phase, however does not bind to denatured single-stranded 
DNA (Rajeevan et al., 2001).  This property can be exploited to verify the specificity of the qPCR 
product through the generation of melting curves by means of plotting fluorescence as a function of 
temperature.  This is performed by slowly increasing the temperature to 95ºC and measuring the 
fluorescence.  A curve is produced as at the lower end of the temperature range there is only a slight 
decrease of fluorescence which then decreases much more quickly at higher temperatures where the 
melting temperature of the amplicon is reached and the DNA is denatured.  The Lightcycler 
programme calculates the first derivatives of the curves, giving rise to curves with peaks at the 
respective melting temperatures.  As the melting temperature of the amplicon depends markedly on 
its nucleotide composition, it is possible to identify the signal obtained from the correct product 
(Bustin, 2000).  Curves with peaks at a lower melting temperature than that of the desired PCR 
product indicate the formation of primer-dimers.  Non-specific products can be seen as diverse 













1. To develop an efficient and practical protocol for the homogenisation of small skin biopsies 
and the extraction of high quality RNA for gene expression analyses 
 
2. To develop a sensitive, reliable, quantitative measure of melanocyte and melanoblast 
survival in vitiliginous skin biopsies utilizing quantitative RT-PCR 
 
3. To determine whether there is a correlation between the presence of melanocytes/ 
melanoblasts in lesional skin and the patient’s response to either potent topical corticosteroid 
therapy or khellin therapy  
 
4. To determine whether there is a correlation between the epidemiological profile of vitiligo 














2. CHAPTER 2: 
 
MATERIALS AND METHODS 
 
2.1 Sources of human tissues 
 
2.1.1 Cell lines and culture 
 
The human melanotic (UCT Mel-1) melanoma cell line was obtained from melanomas excised at 
Groote Schuur Hospital, Cape Town and established by the Department of Clinical Science and 
Immunology, UCT (Hoal, 1981).  The HERMES primary cultured melanocytes were a kind gift 
from Dr Dorothy Bennet, St Georges University of London.  The keratinocyte cell line (HaCaTs) 
was generously provided by Dr Fusenig, Germany (Boukamp et al., 1988).  Both melanoma and 
keratinocyte cell lines were grown in 100mm petri-dishes (Corning, Acton, USA) with Dulbeco’s 
Minimum Essential Medium (DMEM) supplemented with 10% fetal calf serum (FCS, Highveld 
Biological, SA), 100IU/ml penicillin (Sigma, USA) and 100µg/ml streptomycin (Sigma, USA) and 
cultured  at 37°C under 5% CO2/95% air and 90% humidity.  The medium was changed twice a 
week until cells were sufficiently confluent for RNA extraction.  The melanoma cell lines were used 
to optimise the RNA extraction and develop the RT-qPCR assay and the keratinocyte cell line was 
used as a negative control.  
 
2.1.2 Skin tissue samples 
 
2.1.2.1 Skin samples for optimisation of protocols 
 
Human skin tissue samples were obtained from Dr K. Adams, a consultant in the Department of 
Plastic Surgery, Groote Schuur Hospital, Cape Town.  These were surplus skin samples from 
patients undergoing abdominoplasty procedures.  These samples were transported on ice and 4mm
2
 
punch biopsies were taken using sterile instruments under sterile conditions.  These biopsies were 
immediately placed into cryotubes and flash-frozen in liquid nitrogen.  The entire protocol was 












2.1.2.2 Skin samples from vitiligo patients 
 
Vitiligo patients were recruited from the Dermatology outpatient department and PUVA clinics at 
Groote Schuur Hospital, Cape Town.  Punch biopsies of 4mm
2
 (mean tissue weight of 13.8 mg) 
were taken from the centre of a vitiligo lesion as well as from the surrounding pigmented skin.  The 
depth of the punch biopsy was 7mm and included subcutaneous fat.  Following cleaning of the skin 
with povidone iodine solution, the skin was infiltrated with 2% lidocaine and adrenaline solution.  
The punch biopsy was taken from the vitiliginous skin and then from the normal surrounding skin 
in order to prevent any contamination of the vitiligo sample with melanocytes from normal skin.  
Samples were removed using sterile forceps and scissors and immediately snap-frozen in a flask of 
liquid nitrogen.  The biopsy samples were then transferred to the liquid nitrogen tank.  Pressure 
and/or a 40% aluminium chloride solution were applied to the biopsy sites in order to gain 
haemostatic control.  Persistent bleeding sites were sutured closed using 4/0 nylon suture material.  
The biopsy sites were then dressed using gauze dressings.  Sutures were removed ten days later.   
 
2.2 Homogenisation of human biopsy specimens 
 
2.2.1 Polytron homogeniser 
 
2.2.1.1 Preparation of the corex tubes 
 
All corex tubes to be used during homogenisation were cleaned in chromic acid overnight, rinsed 
ten times with tap water and then three times with distilled water.  They were then dried in an oven 
at 80°C for 30 mins.   The tubes were then siliconised in order to prevent any tissue or RNA from 
sticking to the inside of the tube.  In a fumehood, the tubes were filled with siliconising fluid (4% 
dichlorodimethyl silan in CCl4) and allowed to soak for five to ten minutes.  The siliconising fluid 
was then removed and the tubes baked in an oven at 180°C for two hours.  They were allowed to 
cool and then rinsed three times with distilled water in order to remove any residual salin.  Lastly, 
the tubes were soaked in 0.01% DEPC at 37°C for two hours or overnight, followed by autoclaving 














2.2.1.2 Cleaning of the Polytron homogeniser 
 
Prior to use, the Polytron homogeniser (Kinematica GmbH., Littau, Switzerland) was washed in 
Deconex.  This entailed submerging the Polytron head in a corex tube filled with Deconex and 
switching the machine on to ensure thorough cleansing.  The homogeniser was then rinsed 
extensively with dH2O followed by sterilisation with 70% ethanol.  Lastly, the Polytron as well as 
the work surface, all reagent bottles and pipettes were wiped with RNAse AWAY (Molecular Bio-
Products, Inc, San Diego, CA) in order to prevent RNA degradation.   This procedure was repeated 
between each biopsy specimen. 
 
2.2.1.3 Homogenisation of skin biopsy samples 
 
The biopsy samples in their cryotubes were removed from liquid nitrogen and weighed prior to 
homogenisation.  A sterile needle was used to place each biopsy sample into separate siliconized 
DEPC-treated corex tubes each filled with 1mL of TriPure extraction reagent (Boehringer 
Mannheim #1667 1665).  These corex tubes were kept on ice.  The cryotubes were re-weighed and 
the weight of the biopsy specimen alone was calculated.  Each biopsy specimen was then 
homogenized three times in three second bursts.  Between each three second homogenisation, the 
corex tubes containing the specimens were placed back on ice for five seconds in order to prevent 
any RNA degradation due to overheating of the samples.  Some samples were more resistant to 
break-down, such as samples from sites such as the back with tough dermal collagen or samples 
with a thicker stratum corneum.  These samples were subjected to further homogenisation with a 
maximum number of five bursts.  It was noted that in samples homogenised more than five times 
RNA degradation occurred.  The homogenised tissue samples in TriPure reagent were then pipetted 
into a labelled Eppendorf tube and kept on ice.  If more than one patient’s skin biopsy samples were 
homogenised at one time, all the vitiliginous skin specimens were biopsied first in order to prevent 
any contamination with melanocytes from the pigmented skin samples.  Quality control experiments 
analysing the level of carry-over contamination during homogenisation consistently confirmed the 
efficacy of the cleaning procedure applied between the processing of each sample.  The Eppendorf 
tubes were then incubated at room temperature for five minutes in order to ensure the complete 












2.2.2 Tissue breakdown by ball-beating with the Tekniva homogeniser 
 
The cryotube containing the skin biopsy sample was removed from the liquid nitrogen tank and two 
sterile 8 mm stainless-steel balls (Bearing Man, Maitland, SA) as well as 1 mL of TriPure was 
added to the tube.  This tube was then inserted into the Tekniva homogeniser (Tekniva, Cape Town, 
South Africa) which was then activated for a 49 second sequence.  This comprised seven cycles of a 
five second ‘on’ phase and a two second ‘rest’ phase.  The ‘on’ phase involved the transmission of 
high-speed (50 Hz), single plain harmonic motion to the stainless-steel ball and subsequent tissue 
breakdown.  The purpose of the ‘rest’ phase was to avoid overheating of the biopsy samples.  The 
homogenate was then transferred to a labelled eppendorf tube and kept on ice. 
 
2.2.3 Enzymatic breakdown of skin biopsy samples 
 
Skin biopsy specimens were placed in a McCartney bottle with 4 mL of 0.45% trypsin, 100IU/ml 
penicillin and 100µg/ml streptomycin as well as 500 µl of RNAse inhibitor (RNAsin).  The samples 
were left at 4°C overnight.  The following morning, the sample was transferred into a 100mm petri-
dish and washed twice with PBS.  Using sterile fine forceps, the epidermis was teased apart from 
the dermis and the dermis discarded.  The epidermal fragment was placed into a labelled eppendorf 
tube containing 50 µl of a 0.02% trypsin and 0.05% EDTA solution as well as 15µl of RNAsin 
RNAse inhibitor (Promega, USA).  The sample was placed on a shaker for four minutes at 37°C.  
Finally, 1 mL of TriPure was added. 
 
2.3 Total RNA Isolation using Tripure reagent 
 
All glassware was autoclaved before use, sterile disposable plasticware and pipettes/tips reserved 
for RNA work only was used and gloves were used at all times.  This RNA extraction method 
utilised the TriPure isolation reagent, a monophasic solution of phenol and guanidine thiocyanate, in 















2.3.1 Total Cellular RNA Isolation 
 
RNA was extracted from confluent 100mm petri-dishes of MEL-1 melanoma cell lines, HERMES 
primary melanocyte cultures and HaCaT keratinocyte cell lines.  Medium was decanted from the 
petri-dishes and the cells were rinsed with 10 mL of PBS.  This was followed by the addition of 1 
mL trypsin/EDTA to disrupt the intercellular bonds and incubation at 37ºC for three minutes to 
facilitate cellular degradation as evidenced by rounding up of the cells.  Another 1 mL of medium 
containing FCS was added to inactivate the trypsin followed by gentle trituration to create a single 
cell suspension.  Cell suspensions were collected in 15ml tubes and centrifuged at 3000 rpm for five 
minutes at room temperature.  The supernatants were discarded and the pellets resuspended in PBS, 
centrifuged again at 3000 rpm for five minutes and finally resuspended in 1ml cold TriPure RNA 
extraction reagent.  The cell lysate was transferred to a 1.5ml Eppendorf tube and allowed to stand 
at room temperature for five minutes.  The protocol continued as described below. 
 
2.3.2 RNA isolation protocol for both skin tissue samples and cells 
 
Following incubation of samples in TriPure reagent at room temperature, 200 µL of chloroform 
(Merck, Germany) was added to precipitate proteins and lipids.  The tubes were vortexed for 20 
seconds, allowed to stand at room temperature for a further 15 minutes, then followed by 15 
minutes of being centrifuged at 12 000g at 4ºC in order to separate the solution into three phases.  A 
volume of 400 µL of the upper clear aqueous phase was removed and transferred to clean 1.5 mL 
Eppendorf tubes.  The RNA was then precipitated from this colourless aqueous phase by the 
addition of 500 µL of cold isopropanol (Merck, Germany) followed by overnight precipitation at -
20ºC.  The following morning, the samples were centrifuged at 12 000g at 4ºC for ten minutes and 
the supernatant discarded.  Pellets were washed with 1 mL of 75% ethanol, vortexed and re-
centrifuged at 12 000g at 4ºC for a further ten minutes.  The ethanol was removed and the excess 
ethanol removed from the RNA pellet by means of vacuum-drying for five minutes followed by 15 
minutes of air-drying and resuspension in 10 µL of distilled water.  The RNA was quantified at A260 
and purity determined with the A260/280 ratio using a NanoDrop ND-1000 spectrophotometer 













2.4 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
A mix containing 1 µg total RNA and 21 pmol/µL oligo(dT)15 (Colter Group, UK) made up to a 
volume of 8.5 µL with distilled water was incubated at 70ºC for five minutes in a Hybaid PCR-
Sprint thermal cycler (Hybaid, UK).  The samples were then transferred to slushy ice for five 
minutes, followed by the addition of a reaction mixture containing 5mM of four deoxynucleotide 
triphosphates (dNTP) (ABgene, USA), 25mM MgCl2 (ABgene, USA), 5 x Maloney-Murine 
leukaemia virus (MMLV) reverse transciptase buffer solution (Promega, USA), 200U/µL of reverse 
transcriptase (Maloney-Murine leukaemia virus; Promega, USA) and 40U/µL RNAsin RNAse 
Inhibitor (Promega, USA) to make up a total volume of 20 µL.  Complementary DNA was then 
synthesised in the Hybaid PCR-Sprint thermal cycler at 42ºC for one hour and the cDNA stored at -
20ºC.  For all reactions, a negative control was included in order to verify a lack of amplicons.  This 
was done by replacing the RNA template of the reverse transcriptase reaction with distilled water. 
 
2.5 Quantitative Real-time Polymerase Chain Reaction (qPCR) 
 
 The polymerase chain reaction (20 µL total volume) was performed as follows:  The 18 µL PCR-
mix consisted of 10.4 µL of distilled water, 1.6 µL MgCl2 (25 mM), 2 µL each of forward and 
reverse primers and 2 µL of SYBR Green (LightCycler DNA Master SYBR Green I kit, Roche, 
Mannheim, Germany).  The primers (Whitehead Scientific, South Africa) used included:  
 5 µM GAPDH forward primer – 5’   GAAGGCTGGGGCTCATTT   3’ 
 5µM GAPDH reverse primer – 5’   CAGGAGGCATTGCTGATGAT   3’ 
 5 µM Tyrosinase forward primer – 5’   GTCTTTATGCAATGGAACGC   3’  
 5 µM Tyrosinase reverse primer – 5’   AGGCATTGTGCATGCTGCTT   3’ 
 5µM TRP-2 forward primer – 5’   GAGGTGCGAGCCGACACAAG   3’  
 5 µM TRP-2 reverse primer – 5’   CGCTGCCAGGTAACAAATGC   3’ 
This PCR-mix was mixed and transferred to a LightCycler capillary to which 2 µL of the prepared 
cDNA was added followed by a short pulse of ten seconds.  The capillaries were then transferred 
into the LightCycler Sample Carousel (LightCycler Faststart 2.0, Roche).   
 
The PCR reaction was carried out under the following conditions for the first cohort of patients:  











at 95º), annealing (3 seconds at 58ºC) and extension (45 seconds at 72ºC) at which point the amount 
of PCR template was quantified.  This was followed by a melting curve where the temperature was 
increased from 65ºC to 95ºC at 0.1ºC/second to determine PCR specificity and finally a cooling 
cycle of 30 seconds at 40ºC.  The PCR cycling conditions for the second cohort of patients included 
an additional step following extension where the target gene was quantified at the higher 
temperatures of 84ºC for tyrosinase and 86ºC for TRP-2 for 5 seconds at the end of each cycle.  
Each sample was run in duplicate and the RT-qPCR protocol repeated to ensure both technical and 
biological reproducibility.  The crossing threshold values were analysed to measure the target gene 
expression by normalizing the gene’s mean CT value to the mean CT value of GAPDH and utilizing 
the 2
-ΔΔCT 
method (Livak and Schmittgen, 2001).  The PCR products, to which 4 µL of fluorescent 
SYBR Gold (Invitrogen, Eugene, Oregon, USA) was added, were then electrophoresed through a 
1.2% agarose gel for two hours at 80V as an additional confirmation of product specificity.  A 
negative control of distilled water was included in each RT-qPCR run in order to exclude false-
positives which may have arisen from contamination of RT-qPCR reagents with cDNA or 
amplicons.   During the optimization of the RT-qPCR protocol, a positive control using UCT-Mel-1 
RNA as RT-PCR template was included. 
 
2.6 Patient treatment and follow-up 
 
Twenty-one vitiligo patients signed informed consent forms to participate in this study (Appendix).  
This sample included a random subset of patients with vitiligo attending either the Groote Schuur 
Hospital (GSH) Dermatology outpatient clinics or the PUVA clinic between August 2007 and 
February 2008.  Groote Schuur Hospital is a tertiary hospital with referrals from primary care 
physicians, peripheral district hospitals, private dermatologists as well as from other specialities 
within GSH.  Patients recruited for this study therefore came from diverse backgrounds.  Both male 
and female patients, regardless of normal skin colour as well as the type and extent of the vitiligo 
were included.  Exclusion criteria included patients who had received any form of topical or 
systemic treatment within the prior six months, patients with leukoderma secondary to other causes, 
pregnant women, as well as patients under the age of 21.  The nature of the study was carefully 
explained and confidentiality and anonymity were assured.  The study was approved by the 
Research Ethics Committee, UCT Medical School, University of Cape Town, South Africa (Ethics 












At the first interview, a full history was elicited from each patient with regard to epidemiological 
factors, possible precipitating factors and facts about the duration and progression of the disorder.  
Thereafter a clinical examination was conducted documenting the sites of the vitiliginous lesions 
and their extent.  An assessment as to the total body surface area involved was determined.  
Baseline photographs of all vitiliginous lesions were taken using a Sony digital camera (Sony 
Digital Mavica MVC-FD51).   
 
Therapeutic modalities were discussed with patients and a treatment was chosen based on previous 
attempted therapies and patient preference.  Financial constraints were also considered as the 
expense of khellin precluded its use in several patients.  Khellin powder was mixed as a 5% 
concentration in aqueous cream by the hospital pharmacy in 100g containers while the clobetasol 
propionate (Dovate, Aspen Pharmacare: Pharma)) and betamethasone valerate (Lenovate, Aspen 
Pharmacare: Pharma) ointments were dispensed in 25g and 15g tubes respectively.  Patients using 
topical corticosteroids were instructed to apply clobetasol propionate ointment to the sun-exposed 
areas of the fore-arms and hands and betamethasone valerate ointment to the face and neck twice 
daily.  These sun-exposed sites were targeted for treatment s lesions in these visible sites resulted 
in a greater degree of distress and self-consciousness.  Vitiligo patients in the khellin arm of the 
study were to apply topical 5% khellin in an aqueous cream vehicle once daily to the same sites, 30 
minutes prior to sun exposure.  Patients were instructed to apply preparations every day including 
cloudy or rainy days.  Patients receiving both therapies were to receive daily sun exposure at noon 
for 15 minutes or until a slight erythema was noted.  These treatments were initiated one week 
following the punch biopsy procedures. 
 
The efficacy of the two treatment modalities was analysed at a three month follow-up visit by the 
principal investigator as well as by the experienced sister conducting the PUVA clinic.  These 
analyses involved evaluation of the extent of repigmentation as well as the assessment of adverse 
effects related to treatment including atrophy, telangiectasia or any burning sensation.  The 
treatment outcome was visually assessed by means of comparison to the patients’ baseline 
photographs.  In addition, this clinical assessment was supplemented by photographs taken under 
the same conditions at the three month follow-up visit.  This allowed for verification at a later date.  
Repigmentation was evaluated as follows:  poor response (0-25% repigmentation), average 
response (25-50% repigmentation), good response (50-75% repigmentation) and excellent response 















3.1 Optimisation of protocols 
 
3.1.1 Optimisation of the RNA extraction protocol 
 
3.1.1.1 Techniques for mechanical disruption of the skin biopsy samples 
 
In order to develop a protocol for determination of melanocyte/precursor cell survival, the biopsy 
samples first needed to be homogenized for RNA extraction.  This is a particular challenge for skin 
samples which are very tough due to their high levels of collagen and which contain high levels of 
RNAses.  For these optimization studies, skin samples from patients undergoing breast reduction 
surgery were supplied by the Department of Plastic Surgery, Groote Schuur Hospital.  As detailed 
in Materials and Methods, 4mm
2
 punch biopsies were taken from the samples which were then 
snap-frozen in liquid nitrogen.  RNA extraction proved to be difficult as the small 4mm
2
 punch 
biopsy samples were resistant to shearing forces.  This necessitated prolonged homogenization 
times which in turn led to increased heat production and thus RNA degradation as shown by 
degraded RNA visible on agarose gels (not shown).   
Therefore, three alternative methods of RNA extraction were attempted: 
1. Homogenization using a Polytron homogenizer (Kinematica GmbH., Littau, Switzerland) 
with the specimen being kept on ice between short bursts of homogenization (as detailed in 
Chapter 2.2.1) 
2. Tissue homogenization using a Tekniva homogenizer (Tekniva, Cape Town, South Africa) 
which provides high speed (50 Hz), single plain harmonic motion to a sterile 8mm stainless-
steel ball (Bearing Man, Maitland, SA) located in a cryovial containing the skin biopsy (as 
detailed in Chapter 2.2.2). 
3. Enzymatic splitting of the skin tissue by means of trypsinisation followed by RNA 
extraction from the epidermis (as detailed in Chapter 2.2.3). 
Each extraction method was carried out a number of times on three different samples each time.  











three extraction techniques were determined using the Nanodrop spectrophotometer and an average 
quantity of RNA per biopsy was calculated (Table 1).  
 
In order for RNA to be used for quantitative RT-PCR measurements, an excellent RNA purity is 
important and an OD260/280 of 2.0 is optimal.  RNA with an OD260/280 < 1.8 is inadequate for 
qPCR and a minimum yield of 1µg of RNA is necessary for RT-PCR.  The RNA yield and purity 
(as an OD260/280) is shown in Table 1. 
 
 Average RNA yield per 
biopsy  
RNA  260/280 ratio 
Polytron homogenizer 3.3 µg 1.9 
Bead beating 3 µg 1.66 
Skin splitting 0.5 µg 1.91 
 
Table 1.  For each method of tissue disruption, the quantity of RNA (µg) and quality of RNA (as an 
OD260/280 ratio) is shown. The RNA was quantified using the Nanodrop spectrophotometer.   
 
It can be seen that the Polytron homogenizer yielded the most RNA per biopsy with an excellent 
RNA purity.  The method of tissue homogenization using the Tekniva homogeniser produced a poor 
RNA purity while enzymatic skin splitting resulted in an insufficient RNA yield per biopsy.   
 
Therefore, for all further studies, the polytron homogenizer was used for the mechanical disruption 
of the skin biopsy samples. 
 
3.1.1.2 Cleaning protocol of the Polytron homogenizer  
 
Since the same Polytron homogenizer had to be used for all samples, it was essential to ensure that 
there was no carry-over of RNA between samples.  In particular, any carry-over from a pigmented 
skin sample to a lesional skin sample could have led to a false positive gene expression result.  In 
order to avoid this eventuality, all lesional skin samples were homogenized prior to the pigmented 











stringent.  The protocol involved rinsing the homogenizer extensively in sterile distilled water 
followed by one rinse with 70% ethanol.  Finally, the homogenizer was rinsed with RNAse AWAY.   
 
In order to demonstrate that no carry-over contamination had occurred, the cleaning protocol was 
carried out following the homogenization of three skin samples.  The polytron tip was then rinsed 
with a control sample of 1ml extraction reagent alone which subsequently underwent the entire 
qPCR protocol using primers for the housekeeping gene GAPDH, tyrosinase as well as TRP-2.   
 
As can be seen in Fig11a, the products of the three skin samples (purple, pink and blue curves) melt 
at the specific temperature of 87-88ºC for GAPDH.  The product from the extraction reagent control 
sample (yellow curve) demonstrates only primer-dimer formation.  A similar picture can be seen in 
Fig11b in which the products of the three skin samples using the primers for tyrosinase (blue, green 
and black curves) melt at the specific temperature of 86ºC.  The lack of a curve at 86ºC for the 
extraction reagent control sample (red curve) indicates that there was no RNA contamination in this 
sample.  This effectiveness of the cleaning protocol was reiterated in the experiment for TRP-2 as 
can be seen in Fig11c.  The products of the three skin samples (green, pink and grey curves) 
demonstrate the expected melting temperature of 89ºC for TRP-2.  The extraction reagent control 
sample (blue curve), however, does not demonstrate a peak at this melting temperature indicating 
that no contamination has occurred. 
 
In this way, the experiment using the control extraction reagent yielded consistent negative results 






































Fig 11.  Melting curves of the quantitative PCR products using primers for the housekeeping gene 
GAPDH (a.), tyrosinase (b.) and TRP-2 (c.).   
 
3.1.2 Optimisation of the RT-qPCR methodology for the detection of TRP-2 mRNA 
 
A skin biopsy is made up of many different cell types of which melanocytes represent only a small 
number.  A specific and highly sensitive RT-qPCR protocol for the detection of melanocytes 
therefore needed to be developed.  The established RT-qPCR cycling conditions for the detection of 
GAPDH and tyrosinase mRNA consistently produced specific products of 119bp (Fig 12, lanes 2 
and 3) and 238bp (lanes 4 and 5) respectively on agarose gel electrophoresis.  The initial RT-qPCR 
cycling conditions for the detection of TRP-2 mRNA however, produced only primer-dimers and a 
low level of product of the incorrect size as evidenced by non-specific product formation on agarose 














Fig. 12.  Agarose gel electrophoresis demonstrating GAPDH, tyrosinase and TRP-2 mRNA 
expression 
 
LANE 1: 1kb marker 
LANE 2: GAPDH mRNA expression in skin sample 1 
LANE 3: GAPDH mRNA expression in skin sample 2 
LANE 4: Tyrosinase mRNA expression in skin sample 1 
LANE 5: Tyrosinase mRNA expression in skin sample 2 
LANE 6: TRP-2 mRNA expression in skin sample 1 
LANE 7: TRP-2 mRNA expression in skin sample 2 
 
This chapter details the optimization of the RT-qPCR cycling conditions for TRP-2 mRNA which 
was critical in the development of a highly accurate molecular assay for the detection of melanocyte 
survival in human skin biopsies. 
 
The quantitative PCR to detect TRP-2 was initially carried out under the following conditions 
(protocol A):  an initial denaturation step at 95ºC for 30s followed by 45 cycles of denaturation at 

























stage the fluorescence was quantified.  This was followed by a melting curve generated using 
temperatures from 65-95ºC in 1ºC increments in order to verify the specificity of amplification.   
 
These cycling conditions were carried out using a melanoma cell line, primary melanocyte cultures, 
a pigmented skin sample, a lesional skin sample and a keratinocyte cell line.  The RT-qPCR 
products were analysed by gel electrophoresis (Fig 13). 
 
 
                                     
 
 
Fig 13.  Agarose gel electrophoresis demonstrating TRP-2 gene expression in a pigmented skin 
sample, lesional skin sample, HERMES primary cultured melanocytes, MEL-1 melanoma cell line 
and HaCaT keratinocyte cell line.  
 
LANE 1: 1kb marker 
LANE 2: Pigmented skin sample 
LANE 3: Lesional skin sample 
LANE 4: HERMES primary melanocyte culture 
LANE 5: MEL-1 melanoma cell line 


























It can be seen that there are no bands that correlated with the expected product size of 476bps.  The 
pigmented (lane 2) and lesional (lane 3) skin samples as well as the primary melanocytes (lane 4) 
and keratinocytes (lane 6) demonstrated primer-dimer formation.  The MEL-1 melanoma cell line 
(lane 5) produced a single band but with an incorrect product size.  In order to optimize the 
detection of TRP-2 gene expression, the RT-qPCR cycling conditions were modified to allow for a 
longer elongation time of twenty seconds (Protocol B). 
 
Increasing the elongation time resulted in a product size of 476bp for melanoma (lane 2) and 
immortalized melanocytes (lane 3).  However, non-specific products were also seen. No product 
was seen in the keratinocyte lane (lane 4). 
 
 
Fig 14.  Agarose gel electrophoresis analyzing TRP-2 gene expression in SYBR gold stained qPCR 
products.   
 
LANE 1: 1kb marker 
LANE 2: MEL-1 melanoma cell line 
LANE 3:   HERMES primary melanocyte culture 
LANE 4:   HaCaTS keratinocyte cell line 
 






















To further optimize, the annealing temperature was decreased to 58ºC and the elongation time was 
increased to 45 seconds (Protocol C, Fig 15). 
 
Both the MEL-1 melanoma sample (lane 2) and the HERMES primary melanocyte sample (lane 3) 
produced a clear single band of approximately 476 bps, confirming the specificity of the transcripts.  
Faint bands at a smaller bp size of approximately 242-320bps indicate a small amount of primer-
dimer formation.  The HaCaT keratinocyte sample (lane 4) shows only non-specific product or 




Fig 15.  Agarose gel electrophoresis of the RT-qPCR products obtained using the modified Protocol 
C cycling conditions.   
 
LANE 1: 1kb marker 
LANE 2: MEL-1 melanoma cell line 
LANE 3: HERMES primary melanocyte culture 
LANE 4: HaCaT keratinocyte cell line 
 
Having established product specificity, the next step was to analyse these samples by RT-qPCR.  In 
Figure 16 it can be seen that both the MEL-1 melanoma cell line (blue curve) and the HERMES 
























verifying that the cycling conditions were optimal.  The HaCaT keratinocyte cell line – a negative 











Fig 16.  Melting curve analysis of the TRP-2 transcript in a MEL-1 melanoma cell line (blue curve), 
HERMES primary melanocyte culture (green line) and HaCaT keratinocyte cell line (pink curve) 
using the modified qPCR cycling conditions (Protocol C).    
 
The next step was to utilise Protocol C to analyse GAPDH, tyrosinase and TRP-2 gene expression 
in skin samples obtained from the Plastic Surgery Department from excess skin removed during 
abdominoplasty procedures. 
 
The qPCR products obtained from these samples were analysed by gel electrophoresis (Figure 17).  
Analysis of the gel indicates specific product formation for all 3 primers with product sizes of 
119bps (lanes 2-4), 240bps (lanes 5-7) and 476bps (lanes 8-10) for GAPDH, tyrosinase and TRP-2 
respectively.  These results were consistently shown in 3 separate skin samples.  While a single 
band only is seen with the GAPDH products, some primer-dimer formation can be seen in the 














Fig 17. Agarose gel electrophoresis of GAPDH, tyrosinase and TRP-2 transcripts obtained during 
qPCR.   
 
LANE 1: 1kb marker 
LANE 2: Skin sample 1:  GAPDH 
LANE 3: Skin sample 2:  GAPDH 
LANE 4: Skin sample 3:  GAPDH 
LANE 5: Skin sample 1:  Tyrosinase 
LANE 6: Skin sample 2:  Tyrosinase 
LANE 7: Skin sample 3:  Tyrosinase 
LANE 8: Skin sample 1:  TRP-2 
LANE 9: Skin sample 2:  TRP-2 
LANE 10: Skin sample 3:  TRP-2 
 
It was thus established that Protocol C was sufficiently sensitive to detect tyrosinase and TRP-2 






























3.2 Analysis of tyrosinase, TRP-2 and GAPDH in lesional and non-lesional skin samples by 
RT-qPCR 
 
The aim of this specific experiment was to utilise Protocol C to analyse vitiliginous and non-
lesional skin samples from vitiligo patients for the presence of melanocyte survival and to assess 
whether there was any correlation between this survival and the patient’s response to treatment.  
Tyrosinase was chosen as a marker of differentiated melanocytes as it is an enzyme involved in 
melanogenesis.  TRP-2 was chosen as a marker of melanocytes as well as of melanoblasts as this 
enzyme is expressed by undifferentiated melanoblasts at day 10 post-coitum in mice. 
 
Vitiliginous and non-lesional skin samples were obtained from ten vitiligo patients prior to the 
instigation of treatment.  These skin samples were then analysed using the optimized RNA 
extraction and RT-qPCR Protocol C cycling conditions as described previously.  
 
Typical melting curve results for tyrosinase and TRP-2 are shown in Figures 18 and 19.  It was 
established that the GAPDH gene product has a melting temperature of 88ºC, the tyrosinase gene 
product a melting temperature of 86ºC (as can be seen in Figure 18) and the TRP-2 gene product a 
melting temperature of 89º-90ºC (as can be seen in Figure 19). 
 
Quantitative PCR was conducted in duplicate for each vitiliginous and non-lesional skin sample.  
Both the pigmented and lesional skin samples demonstrated positive results for GAPDH with the 
amplicons melting at the above-mentioned melting temperature.  The pigmented skin samples also 
demonstrated positive results for tyrosinase and TRP-2 without exception and thus could be used as 
positive controls.  With regard to the lesional skin samples, the presence of a peak at the correct 
melting temperature of the gene of interest was interpreted as a positive result (Figure 18a and 
Figure 19a).  The absence of a peak at this melting temperature was interpreted as a negative result 






















Fig 18.  Melting curves of the tyrosinase gene product for pigmented (red and grey curves) and 
lesional (green and pink curves) skin samples.  The pigmented skin samples demonstrate the 
specific Tm of 86ºC. a. Lesional skin samples are positive for tyrosinase as demonstrated by the 
melting peaks at the specific melting temperature of 86ºC of the tyrosinase gene product.  b. 
Lesional skin samples are negative for tyrosinase as demonstrated by the lack of any peak at the 





































Fig 19.  Melting curves of the TRP-2 gene product for pigmented (red and grey curves) and lesional 
(green and pink curves) skin samples.  The pigmented skin samples demonstrate the specific Tm of 
89º-90ºC.  a. Lesional skin samples are positive for TRP-2 as demonstrated by the melting peaks at 
the specific melting temperature of 89º-90ºC of the TRP-2 gene product.  b. Lesional skin samples 
are negative for TRP-2 as demonstrated by the lack of any peak at the 89º-90ºC melting 
temperature. 
 












3.3 Profile of the first patient cohort 
 
Ten patients with generalized vitiligo were recruited from the Groote Schuur Hospital outpatient 
department.  These patients had received various treatments in the past, including PUVA, 
corticosteroids or khellin with variable responses ranging from no response (subjective rating of ‘0’) 
to complete repigmentation (subjective rating of ‘10’).  The patients were predominantly female 
(70%) with a mean age of 47 years (with a range of 23 to 70 years).  The mean duration of the 
vitiligo was 16 years (ranging from one year to 45 years) with 4/10 patients (40%) classifying their 
disease activity as stable.  For the purposes of this study, vitiligo is classified as ‘stable’ when the 
following three parameters are fulfilled: 
 There have been no new areas of depigmentation or enlargement of pre-existing lesions 
during the previous six months 
 There has been an absence of the Koebner phenomenon during the previous six months.  
The Koebner phenomenon refers to the development of new depigmented vitiliginous 
lesions in lines of trauma. 
 The patients have reported episodes of spontaneous repigmentation within leukodermic 
lesions within the previous six months 
The majority of the patients had Fitzpatrick skin type IV.  A family history of vitiligo was found in 
2/10 (20%) of patients.  The number of patients with concomitant auto-immune disorders was 
higher than the current statistics of 13% (James WD et al., 2006) with 5/10 patients (50%) having 
been diagnosed and treated for conditions including rheumatoid arthritis, hypothyroidism, diabetes, 









































1 54 M 45 Generalised Stable IV Nil Nil 2001: PUVA 6 
2 41  F 18 Generalised Stable IV Nil Rheumatoid 
arthritis 
1997: PUVA 0 
3 70 F 1 Generalised Active V Nil Nil 2006: PUVA 0 
























7 43 M 25 Generalised Active IV Nil Diabetes 2004: PUVA 1 





9 42 F 14 Generalised Stable IV Brother Allergic 
rhinitis 
2001: PUVA 7 







Table 2.  Epidemiological profile of the first cohort of vitiligo patients 
 
3.4 Melanocyte survival and response to treatment in the first cohort of patients 
 
The next aim was to utilise the optimised RT-qPCR protocol for assessment of melanocyte survival 
in vitiligo skin biopsies and to determine whether there was any correlation between this 
melanocyte survival and response to treatment in vitiligo patients. 
 
Ten patients with generalized vitiligo were recruited from the adult outpatient and PUVA clinics at 
Groote Schuur Hospital in Cape Town, South Africa.  Pregnant female and lactating mothers, 
patients with serious concomitant diseases, patients with a history of keloidal tendency or 
koebnerisation and patients less than 18 years of age were excluded from the study.  The study 












In consultation with the patient, the two biopsy sites were chosen.  In order to prevent an unsightly 
cosmetic result, the face and hands were excluded as biopsy sites.  This was an unavoidable 
limitation whereby the vitiligo lesions analysed for melanocyte survival were not always the sites 
treated.  However, it was hoped to assess whether analysis of any single vitiligo lesion could be 
used to prognosticate on the leukoderma on the whole.  A 4mm
2
 punch biopsy was taken from the 
centre of a vitiligo lesion as well as from an adjacent area of pigmented skin.  (as detailed in 
Chapter 2.1.2.2)  These pigmented and lesional samples were then analysed by the optimized RT-
qPCR protocol for tyrosinase and TRP-2 mRNA expression developed as described in Results 
Section 3.1.2.  Both technical and biologic repeat experiments were conducted.  Melting curves 
were examined to confirm specificity of product.  A sample was considered positive for tyrosinase 
if the melting temperature peak was at 86ºC and positive for TRP-2 if the melting temperature peak 
was 89-90ºC.  Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a positive 
internal control. 
 
Therapeutic options were discussed with each patient.  It was decided to treat only the areas of the 
body receiving sun exposure, namely the face, neck, fore-arms and hands.  Potent topical 
corticosteroid treatment was initiated in 9/10 patients due to its affordability.  Patients were 
instructed to apply betamethasone ointment to the face and neck region and clobetasol priopionate 
ointment to the forearms and hands twice daily.  In 1 patient, a 5% khellin solution was to be 
applied once daily prior to sun exposure.  All patients were to receive a daily dose of sun exposure 
at noon either for 15 minutes or until a mild erythema was noted.  All ten patients completed the 3 
month trial.   
 
In all patients, clinical photographs were taken and an assessment of body surface area involvement 
of the face, forearms and hands was made by both the principal investigator and an experienced 
sister conducting the PUVA clinic.  This was performed both prior to the initiation of treatment as 
well as at the end of the 3 months.  At the conclusion of the treatment period, the response to 
treatment in each patient was assessed as being either a poor response (<25% repigmentation), 
average response (25-50% repigmentation), good response (50-75% repigmentation) or excellent 
response (>75% repigmentation) as has been detailed in Chapter 2.6. 
 
Table 3 records the results obtained for the detection of tyrosinase and TRP-2 in lesional skin of 











therapy.  It can be seen that melanocyte survival was found in 6/10 (60%) of vitiligo patients.  A 
poor response to treatment (<25% repigmentation of the sun exposed areas after 3 months of 
treatment) was seen in 7/10 (70%) of patients while 1 patient (10%) had an average response to 
treatment (25-50% repigmentation) and 2/10 patients (20%) had a good response to treatment (50-
75% repigmentation).  No patient achieved an excellent (>75% repigmentation) response to 
treatment.  No correlation between melanocyte survival and response to treatment was found in this 
cohort of patients. 
 Pt  Biopsy       
 Site 
Tyrosinase  TRP-2        Treatment  % Repig  Before                                After 





 2   Fore- 
 Arm 




 3  Thigh  -ve  -ve  Cortico- 
 steroids   
 50-75% 
  




 5  Fore- 
 Arm 
 















 Pt  Biopsy       
 Site 
Tyrosinase  TRP-2        Treatment  % Repig  Before                                After 








 8  Back  -ve  +ve  Khellin  <25% 
  
 9  Thigh  -ve  +ve  Cortico- 
 Steroids 









Table 3.  Presence of melanocytes/melanoblasts in lesional skin and response to treatment in the 
first cohort of vitiligo patients.   
 
When analyzing tyrosinase and TRP-2 expression in the vitiliginous skin biopsies, it was found that 
only the presence or absence of transcript in these skin samples could be evaluated due to a 











measurement of fluorescence yielded by the dye binding to dsDNA during extension.  Analysis of 
the melting curves (Figure 18a) and of agarose gel electrophoresis (Figure 17) indicated that at the 
extension temperature of 72ºC, high levels of primer-dimers were present and there was still 
significant non-specific product formation with TRP-2.  This would increase the fluorescence, 
thereby giving incorrect crossing threshold values and thus incorrect quantitation.  Since this was a 
critical aspect in the development of an accurate prognostic assay for vitiligo patients, it was crucial 
to achieve finer optimization.  Therefore, prior to conducting a study with a new cohort of patients, 
it was decided to optimize the RT-qPCR cycling conditions further in order to eliminate these 
confounding contaminants.                       
 
3.5 Elimination of primer-dimers 
 
The crossing threshold (CT) in quantitative PCR is defined as the point at which the fluorescent 
signal is first detected as statistically significant above background.  In this way, the greater the 
amount of template present at the beginning of each reaction, the fewer the number of cycles it 
takes to reach the crossing threshold (Freeman et al., 1999).  This crossing threshold value can then 
be used to analyse the relative change in gene expression of an experimental sample to that of a 
control sample by means of the 2
-ΔΔCT method (Livak and Schmittgen, 2001).   
 
The presence of primer-dimers or any non-specific product, however, contributes to the fluorescent 
signal resulting in a lower CT value and consequently invalidating any relative quantification.  The 
aim was thus to eliminate the fluorescence produced by primer-dimers during RT-qPCR.  . 
 
As previously described, the melting curve analyses revealed that the primer-dimers melted at a 
lower temperature compared to the desired amplicon due to their smaller size.  The Tm of the 
tyrosinase transcripts was 86ºC compared to the approximate Tm of 80ºC of the primer-dimers (as 
seen in Fig 18).  In the case of TRP-2, the melting temperatures of the transcripts vs primer-dimers 
were 89ºC and 84ºC respectively (as seen in Fig 19).  The strategy was therefore to utilize the 
LightCycler’s ability to measure fluorescence at a higher temperature than the melting point of the 
primer-dimers in order to ensure that the fluorescence of only the desired amplicon was measured. 
The initial cycling conditions of Protocol C was comprised of 45 cycles of denaturation at 95ºC for 
5 s, annealing at 58ºC for 3 s and elongation at 72ºC for 40 s after which fluorescence was measured 













Fig 20.  The initial qPCR cycling conditions of Protocol C for amplification of tyrosinase and TRP-
2 cDNA.   
 
In order to take advantage of the lower melting temperature of the primer-dimers and the 
Lightcycler’s ability to measure fluorescence at any temperature, an additional step was added to 
the qPCR cycling conditions of Protocol C in order to prevent primer-dimer interference.  This 
modified protocol – Protocol D – is depicted in Figure 21.   
 
Following the initial qPCR cycle, the temperature was raised to 84ºC (tyrosinase) or to 86ºC (TRP-
2) for 5 s after which the fluorescence was measured (Figure 21).  At these temperatures there is 
denaturation of the primer-dimers but not of the specific qPCR product.  As SYBR Green binds 





































Fig 21.  The modified qPCR cycling conditions used to eliminate the fluorescence elicited by 
primer-dimers (Protocol D). 
 
In order to demonstrate that the modified cycling conditions of Protocol D successfully eliminate 
primer-dimer contribution to the total fluorescence, the amplification data from Protocol C and D 
were compared. 
 
The same skin samples were analysed using the initial (Protocol C) and modified (Protocol D) 
cycling conditions (Fig 22). Figure 22a depicts the amplification data using Protocol C.  The 
fluorescence can be seen to increase to almost 8 after 45 cycles with an average crossing threshold 
value of 36.2.   
 
In contrast, the amplification data using Protocol D indicates a much lower relative fluorescence (as 
can be seen in Figure 22b).  The fluorescence was measured as approximately 4.5 after 45 cycles 
with an average crossing threshold value of 29.  This decrease in fluorescence and subsequent 
decrease of approximately 20% in the crossing threshold values proves that the elimination of 
primer-dimers is accomplished by means of this strategy.  For the purposes of this study, all further 





























































Fig 22.  a.  Representative experiment showing total fluorescence measured at the end of each 
qPCR cycle using the initial qPCR protocol (Protocol C).    b.  Representative experiment showing 
total fluorescence measured at the end of each qPCR cycle using the modified qPCR protocol 
(Protocol D).   
 
The resolution of the above technical problem of primer-dimers allows quantification of 
melanocyte/melanoblast survival in vitiliginous skin.  An additional patient cohort was therefore 












3.6 Profile of the second patient cohort 
 
Eleven patients consented to participate in the study and all eleven completed the three months of 
treatment.  The ages of the patients ranged from 25 to 69 years (mean age of 45 years) and the 
duration of the disease varied from 2 to 49 years (mean duration of 12 years).  Ten patients had 
generalized vitiligo vulgaris while 1 patient had vitiligo universalis.  In 7/11 patients (64%), the 
disease was progressive, while in 4/11 patients (36%), vitiligo was stable.  Stable vitiligo was 
defined as showing neither spread of existing lesions nor development of new lesions during the 
previous 6 months. Most patients were classified as having Fitzpatrick skin type III or IV.  The 
majority of the patients – 9/11 (82%) – were male while 2/11 patients (18%) were female.  A family 
history of vitiligo was found in 3/11 patients (27%), while 4/11 patients (36%) had additional 
concomitant auto-immune disorders including diabetes, asthma, psoriasis and rheumatoid arthritis.  
The questionnaire completed by the patients prior to the initiation of treatment included a history of 
previous therapies as well as their subjective response to that therapy rated on a scale from 0 (no 
response) to 10 (100% repigmentation.)  Prior therapies included khellin, corticosteroids, PUVA 
and elocon and the subjective assessment of response to tre tment ranged from 0 to 10.   
 



















1 49 M 7 Generalised Active III Nil Diabetes 2006: Khellin 5 
2 46  M 10 Generalised Active III Nil Nil 1997: Elocon 7 
3 55 F 49 Vitiligo 
universalis 
Stable IV Nil Nil PUVA Unsure 
4 43 M 5 Generalised Stable III Nil Asthma PUVA 6 
5 33 M 6 Generalised Stable VI GM Nil Khellin 10 












8 64 M 6 Generalised Active IV Uncle 
Cousin 
Nil 2005: Khellin 4 




10 45 M 2 Generalised Active III Nil Nil 2006: Khellin 0 
















3.7 Melanocyte survival and response to treatment in the second patient cohort 
 
The next aim was to investigate whether quantification of melanocyte survival could be used as a 
prognostic assay for vitiligo patients prior to the initiation of therapy.   The ability to predict a 
vitiligo patient’s response to therapy would enable the clinician to develop an appropriate 
management plan.  The clinician would also be able to advise the patient as to whether the time-
consuming and expensive treatment options available would be judicious.     
 
Eleven patients from the Groote Schuur outpatient and PUVA clinics consented to participate in this 
study.  The same exclusion criteria described in Results Section 3.4 were applied.  The optimized 
RT-qPCR protocol which effectively eliminated primer-dimers and non-specific products (Protocol 
D) was then used to analyse lesional and pigmented skin samples obtained by means of 4mm
2
 
punch biopsies.  Lesional skin samples which demonstrated a peak at the correct Tm of 86ºC for 
tyrosinase gene expression and 89-90ºC for TRP-2 gene expression were assessed as exhibiting 
melanocyte/melanoblast survival.  In these samples, the percentage melanocyte survival in 
vitiliginous skin was calculated in relation to expression in non-lesional skin using the 2
-ΔΔCT
 
method (Livak and Schmittgen, 2001) by calculating the relative changes in tyrosinase and TRP-2 
expression. 
 
The eleven patients were randomized into two groups:  one group receiving potent corticosteroid 
ointment as described in Results Section 3.4 (group I) and the other group receiving a topical 5% 
khellin solution (group II).  Both groups were instructed to have daily sunlight exposure at noon for 
15 mins or until a mild erythema developed.  The response to treatment in both groups was 
evaluated by serial photographic record.  Repigmentation of the treated areas was recorded as poor 
(<25%), average (25-50%), good (50-75%) or excellent (>75%) depending on the extent of 
repigmentation. 
 
Table 5 illustrates the relative changes in tyrosinase and TRP-2 gene expression of lesional skin 
samples determined from the RT-qPCR experiments as well as the patients’ responses to either 
potent corticosteroid or khellin treatment.  It can be seen that in 6/10 vitiliginous samples, the 
presence of melanocytes was demonstrated.  In 4 patients both tyrosinase and TRP-2 gene 
expression was found, while 1 patient demonstrated tyrosinase gene expression alone and another 











calculated as a percentage of the expression in pigmented skin, it was found to range from 4% to 
46% survival.   
 
 Pt  Biopsy    
 Site  
Tyrosinase  TRP-2  Treatment  % Repig  Before                                After                                      
 1  Lower 
 Limb 
     23%  11%  Khellin  50-75% 
  
 2  Axilla     -ve  -ve  Khellin    <25% 
 
 
 3  Fore- 
 Arm 
     8%  10%  Cortico-  
 steroids 
   <25% 
  











 5  Flank     -ve  -ve Corticoster
oids 








 6  Lower 
 Limb 












 Pt  Biopsy 
 Site 
 Tyrosinase  TRP-2  Treatment  % Repig  Before  After 
 7  Fore- 
 Arm 
    -ve  -ve  Cortico- 
 steroids 
   <25% 
  
 8  Fore- 
 Arm 
    -ve -ve  Cortico-  
 steroids 
   <25% 
  
 9  Lower 
 Limb 
    46% -ve  Cortico- 
 Steroids 
   <25% 
  
 10  Lower 
 Limb 




 11  Knee     15%  4%  Khellin  25-50% 
  
 
Table 5.  Percentage of melanocyte/melanoblast survival in lesional skin and response to treatment 













In order to determine whether a correlation between melanocyte survival and percentage 
repigmentation exists, a scatter graph was plotted (Fig 23).  The Y axis depicts the percentage 
tyrosinase and TRP-2 gene expression found in lesional skin while the X axis demonstrates the 
percentage repigmentation following three months of topical corticosteroid or khellin therapy. The 
percentage gene expression shown here represents an average of the tyrosinase and TRP-2 gene 
expression found in lesional skin samples as calculated using the 2
-ΔΔCT 
method.  For example, in 
patient 3, RT-qPCR demonstrated a lesional tyrosinase and TRP-2 gene expression of 8% and 10% 
respectively relative to the gene expression found in the pigmented control samples. The percentage 
gene expression value plotted on to the scatter graph for patient 3 was therefore the value of 9%.  
The need to use an average of tyrosinase + TRP-2 gene expression was unavoidable as a disparity 
existed between the RT-qPCR values in vitiliginous skin for each gene separately.  This is 
especially evident in patient 6 (Table 5) who demonstrated no lesional TRP-2 expression but who 
had a relative tyrosinase value of 30% compared to the pigmented skin sample.  Similarly patient 9 
exhibited a TRP-2 relative gene expression of 46% but no tyrosinase expression. Since both these 
genes represent markers of melanocyte survival, an average of the two values was felt to best 
represent the extent of this survival. The objective was to ascertain the value of the average 
vitiliginous skin gene expression value above which a patient was likely to demonstrate >50% 
repigmentation.  For example, the scatter graph shown in Fig 25a depicting the correlation between 
% melanocyte survival and % repigmentation following treatment with khellin demonstrated a 
correlation coefficient R
2
 = 0.8919.  From this correlation curve, it could be deduced that an average 
tyrosinase and TRP-2 gene expression value of 10% indicates an adequate melanocyte reservoir 
whereby >50% repigmentation following treatment with the appropriate therapeutic agent could be 
expected.  Although the correlation curve in Fig 23 shows that no correlation exists (R
2
 = 0.1257), 
there does appear to be a trend between the presence of melanocytes and response to treatment.  It 













Fig 23.  Scatter graph demonstrating the correlation between the % tyrosinase and TRP-2 gene 
expression in stable(   ) and active (   ) vitiliginous lesions and % repigmentation in vitiligo patients 
following either potent corticosteroid or khellin therapy (R
2
 = 0.1257).   
 
 
From the scatter graph depicted in Figure 23, it can be seen that there are 2 conspicuous outlying 
values influencing the correlation curve (see blue arrows).  There are explanations for both of these 
cases.   
 
In the first case (patient 5), the biopsy sample was taken from the flank area whereas the treated 
sites showing excellent (>75%) repigmentation were those only which were sun-exposed (face, 
neck and fore-arms).  It is important to keep in mind that the biopsy of visible sites such as the face 
or hands is undesirable in all patients.  It was therefore of value to establish whether the biopsy from 
any site could be used to prognosticate the state of melanocyte survival in general.  It can be 
hypothesized however, that the fate of the melanocytes varies from lesion to lesion in vitiligo 
patients, particularly when taking the age of the lesion into account.   
 
With regards to the second case (patient 9), it can be seen from Table 4 that while this patient had 
showed poor response to treatment with khellin, he had demonstrated a good response to PUVA 
therapy in 2006.  This therapy was stopped due to financial constraints.  It is a common and 







































results emphasise this heterogeneity of patient responses to different treatment options.  Evidence of 
melanocyte survival should therefore prompt the physician to persevere with alternative treatment 
modalities should one therapy fail.  
 
In Figure 24, the scatter graph depicted in Figure 23 was re-plotted excluding the two outlying 
values.  As can be seen, there is a significant correlation (R
2
 = 0.77) between melanocyte survival 
and response to treatment.  Thus this small-scale study suggests that analysis of vitiligo lesions prior 
to initiating treatment might have value in predicting patients’ responses to therapy.  Also of note is 
that the activity of the vitiligo lesion (active vs stable) does not seem to impact the correlation 
curve. 




























Fig. 24.   Scatter graph demonstrating a significant correlation (R
2
 = 0.77) between the % tyrosinase 
and TRP-2 gene expression in stable (   ) and active (    ) vitiliginous lesions and % repigmentation 
following treatment. 
The next aim was to assess whether the different treatment modalities of khellin and corticosteroids 
had any impact on the degree of repigmentation. 
 
In 2/5 (40%) of patients treated with khellin and 2/6 (33%) of patients treated with corticosteroids, 
more than 50% repigmentation was seen.  It appears that patients in both the corticosteroid and 
khellin arms of the study demonstrated comparable degrees of repigmentation.   
 
Independent scatter graphs were then plotted in order to determine whether the modality of 













seen in Figure 25a that a strong correlation (R
2
 = 0.8919) exists in patients receiving khellin 
therapy.  Conversely, in Figure 25b, no correlation can be found in patients applying corticosteroid 
ointments (R
2
 = 0.169).  It is important to take into account, however, that the 2 outlying values 
discussed above were both in the corticosteroid arm of the study, thereby affecting this correlation 







































































Fig 25.  a.  Scatter graph depicting the correlation between % melanocyte survival and % 
repigmentation following treatment with khellin (R
2
 = 0.8919).  b.  Scatter graph depicting the lack 
of correlation between % melanocyte survival and % repigmentation following corticosteroid 
therapy (R
2
















Vitiligo is a depigmentation disorder of cosmetic importance with bearing on the psychological 
well-being and self-esteem of its sufferers. The treatment of this condition remains frustrating for 
innumerable reasons.  The most salient of these is a lack of insight into the aetiopathogenesis of this 
condition.  This is compounded by a lack of understanding of the mechanisms of actions of the 
available treatment options.  Together, these critical gaps in our knowledge result in empirical 
therapies which might or might not target the underlying pathology.  The ground-breaking 
discovery of the melanocyte stem cell ‘niche’ in the hair follicle explains the typical pattern of 
perifollicular repigmentation seen in vitiligo patients following PUVA therapy.  But it still doesn’t 
explain the dynamics of repigmentation or the question of why certain patients respond to treatment 
and others do not.  In an attempt to marry science and clinical experience, the experimental 
approach of this study was to analyse the status of melanocytes in vitiliginous skin prior to the 
initiation of treatment utilizing the molecular technique of RT-qPCR.  Tyrosinase and TRP-2 were 
chosen as markers of differentiated melanocytes and of melanocyte precursors respectively.  The 
clinical responses to two different treatment modalities with allegedly different, albeit largely 
unknown, mechanisms of action were then assessed and correlated to the molecular profile of the 
vitiligo lesions.  It was hoped to utilize our growing understanding of melanocyte biology, in 
particular the stem cell niche and to relate this to therapeutic options for vitiligo patients.  
Ultimately, it was hoped to establish a viable prognostic test to help clinicians plan a rational 
therapeutic approach for their vitiligo patients.  In the pursuit of this objective, questions asked in 
this study were: 
 
a. Can the quantification of melanocyte and melanoblast survival be correlated with patient 
outcomes? 
 
b.  Do lesions with demonstrated melanocyte survival respond differently to different 
treatments:  either potent topical corticosteroid therapy (with immunomodulatory properties) 












c. Can this quantification be utilized as a feasible prognostic test in terms of its efficiency, 
reliability, sensitivity and cost-effectiveness (i.e. proof of principle)? 
 
d. Does the epidemiological profile of vitiligo patients contribute to the prediction of likely 
therapeutic response? 
 
4.1 Development of a more sensitive, quantitative measure of melanocyte/ melanoblast 
survival in vitiliginous biopsies 
 
The question of whether vitiligo lesions are completely devoid of melanocytes remains in dispute.  
In 2007, Gottschalk and Kidson published a pilot study analysing melanocyte survival in vitiligo 
patients utilizing molecular techniques.  They found that only 25% of vitiliginous lesions were 
positive for tyrosinase and/or TRP-2 mRNA expression.  However, clinical studies report that 30-
75% of vitiligo patients respond to treatment.  This suggests that either the presence of 
melanocytes/melanoblasts is not a good prognostic test and/or that this low detection rate was due to 
technical limitations of the molecular assay and/or the sample size of this study (n=12) was too 
small.  This study aimed to distinguish between these possibilities and to expand the data pool.   
 
In order to achieve this, RT-qPCR was utilized to quantitate melanocytes and melanoblasts in 
vitiliginous skin more accurately.  To optimize the protocol, lesional and non-lesional skin biopsies 
were taken from 10 vitiligo patients prior to the initiation of either potent topical corticosteroid or 
topical khellin therapy in combination with daily sunlight exposure.  The accurate analysis of 
tyrosinase and TRP-2 gene expression of these biopsy samples proved to be challenging owing to a 
number of reasons. 
 
The first difficulty was the resilience of frozen skin biopsy specimens which proved very tough, 
resisted homogenization and which were prone to degradation owing to endogenous RNAses.  This 
resulted in incomplete sample disruption and sample loss.  These problems were exacerbated by the 
fact that the punch biopsy specimens were only 4mm
2
 and had an average weight of only 13.8mg.  
Homogenisation procedures therefore had to be optimized.  It was found that three cycles of 
homogenization of three seconds each with five second intervals of cooling on ice provided optimal 
results.  This protocol combined with stringent RNA protection measures resulted in the satisfactory 











importantly, all of the skin biopsy specimens yielded usable data utilizing this homogenization 
technique.  This is a significant improvement over prior RNA extraction procedures from skin 
biopsies such as Cole et al., (2001) where utilizable RNA from breast skin biopsies was extracted in 
only 56% of the biopsies. 
 
The next technical probem was the formation of non-specific products or primer-dimers during 
qRT-PCR analysis.  At the extension temperature of 72ºC, high levels of primer-dimers were 
present.  RT-qPCR using SYBR Green works on the principle of measurement of fluorescence 
resulting from the dye binding to dsDNA during extension.  Primer-dimer formation therefore 
results in an increase of the fluorescence, thereby giving incorrect crossing threshold values and 
thus incorrect quantitation.   
 
Since all the RNA from the first patient cohort had been used, it was necessary to recruit a second 
cohort of patients for further skin biopsy samples and to re-optimise the RT-qPCR methodology in 
order to eliminate these primer-dimers.  To do this, the Light-Cycler’s capacity to differentiate 
between the melting temperatures of the gene product of interest and the incidental primer-dimers 
was exploited.  The strategy used a modification of the RT-qPCR cycling programme to include a 
primer-dimer melting step which effectively eliminated the primer-dimer fluorescence.  This 
strategy resulted in a 20% decrease in the crossing threshold values and confirmed that the 
fluorescence of only the desired amplicon was measured.    
 
Using this methodology, it was demonstrated that there was tyrosinase and/or TRP-2 gene 
expression in 60% of lesional skin biopsies (n=21).  In 5/21 patients, both tyrosinase and TRP-2 
were expressed, indicating the presence of eumelanin-producing melanocytes.  In 4/21 patients, 
TRP-2 was expressed alone, indicating melanoblast survival, while in 3/21 patients only tyrosinase 
was expressed.  When compared to the result of Gottschalk and Kidson, (2007), where only 25% of 
samples were positive for tyrosinase and/or TRP-2 gene expression (n=12), the percentage survival 
found in this study is much higher.  This strongly supports the superior sensitivity of the RT-qPCR 
protocol.  When this gene expression in lesional skin was calculated as a percentage of the 
expression of the pigmented skin of the same patient (using 2
-ΔΔCT 
) , it was found to range from 8% 
to 46% for tyrosinase and from 4% to 30% for TRP-2 (n=11).  It was hoped to determine whether 
the level of these lesional gene expression values would correlate with successful repigmentation 











If so, these values would provide a much needed prognostic tool to guide dermatologists in planning 
an appropriate therapeutic course of action.  
 
The finding in three patients that only tyrosinase (and not TRP-2) was expressed is surprising.  
There are two possible reasons for this result:  it could represent either a technical inaccuracy or the 
presence of pheomelanin-producing melanocytes.  The more likely explanation is a technical issue 
as opposed to a biological one.  This is supported by the fact that following further fine-tuning of 
the RT-qPCR protocol for the second cohort of patients, an increased number of patients 
demonstrated expression of both enzymes together (4/11) as compared to the first cohort of patients 
(1/10).  This also suggests that additional optimization of the RT-qPCR protocol is required to 
provide a more sensitive and more precise molecular assay and that caution is needed when 
interpretating this study’s results.    
 
4.2 Is there a correlation between melanocyte survival and response to treatment? 
 
After obtaining the biopsies indicated above, the patients were initiated on either potent topical 
corticosteroid or topical khellin therapy.  For both groups, 15 minutes daily sun exposure at noon 
was stipulated.  The percentage repigmentation achieved following three months of treatment was 
recorded and plotted against the pre-treatment tyrosinase and TRP-2 gene expression values of the 
vitiliginous lesions.  When all the samples were plotted, the results did not show any correlation 
between melanocyte/melanoblast presence and response to treatment, although a trend can be 
appreciated.   
 
On closer scrutiny of the scatter graph, two outlying values which influence the correlation curve 
are conspicuous.  A strong correlation becomes clearly apparent upon the exclusion of these two 
outlying values (R² = 0.77).  This highlights three study design flaws.   
 
1. The first experimental design fault is the fact that the site biopsied was not always the same 
site that was treated.  This was the case for the first outlying value where the biopsy site (the 
flank area) was not within the area receiving treatment (only the sun-exposed areas).  The 
first critical modification of the study design for future research purposes would therefore be 











2. The second design flaw is that only one treatment modality was attempted for each patient.  
It is a common and inexplicable finding that vitiligo patients’ responses to treatment are 
heterogenous and that they will respond to one therapeutic modality and not to another.  The 
patient representing the second outlying value, although demonstrating no response to 
topical corticosteroid therapy in this trial, had in the past responded to a different treatment 
modality.  This raises the issue of the length of follow-up.  The second modification of a 
future study would therefore be to utilize a prospective study design with a longer follow up 
period in order to allow for various treatment options to be attempted.   
3. The final experimental design flaw relates to the small sample size of this study, as is 
highlighted by the fact that the correlation curve could be so greatly influenced by only two 
outlying values.  The third modification would therefore be to recruit a greater number of 
patients, in order to attain statistically significant results from which concrete conclusions 
can be drawn. 
 
 A significant correlation was found when considering melanocyte survival in the cohort of patients 
receiving khellin therapy (R² = 0.8919).  This is more likely to be because the two outlying values 
described above were both in the corticosteroid arm of the trial and thus were not distorting the 
correlation curve in the khellin group, rather than any significance in these two therapies’ 
presumedly different mechanisms of action in vitiligo.  
 
4.3 Which therapy, topical corticosteroids or topical khellin, combined with sunlight has a 
better therapeutic response? 
 
Topical corticosteroids have been used as a first-line treatment for vitiligo during the last three 
decades.  The low cost, ease of application and high rate of adherence are the benefits of using this 
treatment.  However, there is a high recurrence rate following cessation of treatment as well as 
adverse side effects such as skin atrophy, telangiectasia and striae.  There is also the risk of 
increased intraocular pressure, glaucoma and cataracts when using potent topical steroids around the 
eyes.  This is significant as vitiligo often manifests in the peri-ocular region.  The advent of KUVA 
phototherapy therefore heralded great hope for both physicians and patients grappling with vitiligo.  
It has been lauded as a safe home-based alternative to PUVA therapy which is often unfeasible due 
to high transport costs and rigid employment hours precluding frequent hospital visits (Valkova et 











exciting therapeutic option.  Its safety profile also makes it a good option for the treatment of 
sensitive areas of the skin such as eyelids.  Its efficacy however remains in dispute. 
 
Corticosteroids and khellin are hypothesized to induce repigmentation in vitiligo patients by 
targeting the auto-immune component or by stimulating melanogenesis respectively.  Due to the 
differences in their alleged mechanisms of actions, it was hoped to determine, in the context of this 
study, which treatment modality was more effective in vitiligo patients and whether this could 
provide any further insight into the aetio-pathogenesis of this disorder. 
 
In this study, 15 patients applied topical clobetasol propionate ointment to the hands and fore-arms 
and betamethosone ointment to the face and neck twice daily while 6 patients applied khellin 
ointment to these same areas daily for a trial period of three months.  In both groups of patients, the 
treatment was supplemented with 15 minutes daily sun exposure at noon.  Following the three 
months of therapy, the repigmentation of the treated areas was found to be excellent 
(repigmentation >75%), good (repigmentation 50-75%), average (repigmentation 25-50) or poor 
(repigmentation <25%). 
 
A good or excellent response of more than 50% repigmentation was seen in 27% of patients (n=15) 
using corticosteroid therapy.  This is markedly lower than that reported in other studies, for example 
Kumari et al., (1984) where 90-100% repigmentation was achieved in more than 80% of patients 
with vitiligo of the face (n-75).  However it is higher than the low response rate reported by Clayton 
et al., (1977), (n=23) where only 9% of patients demonstrated >75% repigmentation.  In addition, in 
this study, one would have expected better response rates by virtue of the treatment area including 
the facial region.  It has been reported that the face demonstrates a superior response when 
compared to other areas of the body as it has a higher concentration of melanocytes and the skin in 
this area is thinner (Milne et al., Unpublished data).  These discrepancies can be explained by study 
design differences, the smaller sample size of this study as well as the different phenotype of the 
patients involved.  The majority of patients in this study had a Fitzpatrick type IV skin phenotype.  
As vitiligo in dark-skinned individuals is known to respond better to treatment (Mandel et al., 
1997), a superior repigmentation response was anticipated.  However, the small patient numbers in 
this study make any comparisons to larger studies difficult.  Other factors limiting comparisons 
include the fact that in some studies, patients received therapy to small patches in isolation whereas 











vary from the repigmentation of single patches to overall repigmentation.  Different compounds 
have been studied with different potencies and differences in the vehicles chosen may also have 
effected the penetration and therapeutic efficacy.   
 
With regards to khellin, this study’s finding of more than 50% repigmentation occurring in 33% of 
patients (n=6) applying khellin ointment corroborates the studies of Orecchia et al., (1999) and 
Valkova et al., (2004) in which 36% and 43.8% of patients respectively experienced a 
repigmentation of greater than 50%.   
 
Comparable degrees of repigmentation were therefore seen in the corticosteroid and khellin groups 
of this study, however it is difficult to make any concrete analyses due to discrepancies in numbers 
between the two treatment arms as well as the small sample size.  Another important limitation of 
this study is the fact that patients received corticosteroid or khellin therapies in combination with 
sunlight.  Ultraviolet radiation is a distinct treatment modality which alone can stimulate 
melanogenesis, melanocyte proliferation and subsequent repigmentation in vitiligo patients.  In 
view of the cost-effectiveness and convenience of sunlight s a treatment modality for vitiligo 
patients, the role of sunlight, as well as its potential risk of increased skin carcinogenesis, requires 
further investigation.  A future experimental design should therefore include control groups 
receiving either sunlight alone or no treatment at all as separate arms of the study.   
 
Another consideration when planning a future design study would be to investigate the efficacy of a 
combination corticosteroid/khellin therapy to ascertain the benefits of their respective 
immunosuppressive and proliferative effects together. Westerhof et al., (1999) compared topical 
fluticasone ointment alone or combined with UVA in 135 adults.  They found that the potent topical 
corticosteroid fluticasone used alone for nine months induced a mean repigmentation of only 9%, 
UVA alone a mean repigmentation of 8% while the combination of fluticasone and UVA induced a 
mean repigmentation of 31%.  Conversely, another study by Lotti et al., (2008) demonstrated a 
lower response rate of vitiligo patients to a combination therapy of betamethasone dipropionate 
0.05% cream twice a day plus 311-nm narrow-band microphototherapy (71.2% demonstrating 
>75% repigmentation after six months therapy) compared to betamethasone dipropionate cream 
alone (90.2% demonstrating >75% repigmentation).  The small number of randomized controlled 
trials comparing combination therapies to monotherapies makes it difficult to draw any conclusions. 











i.e. a topical corticosteroid and a photosensitizer – i.e. khellin would provide a greater 
repigmentation response than either therapy alone, particularly in patients demonstrating 
melanocyte survival.   
 
4.4 Is there a correlation between the epidemiological profile of vitiligo patients and their 
response to therapy? 
 
Vitiligo is heterogeneous in its aetiopathogenesis, in its natural history and in its response to 
therapy.  It has been proposed that different pathogeneses might underlie the different clinical 
phenotypes thus explaining their variable responses to treatment.  This study hoped to establish 
whether any characteristics in the epidemiological profile of vitiligo patients could have prognostic 
implications. 
 
The clinical profile of the 21 vitiligo patients included in this study is that of generalized vitiligo 
(one with vitiligo universalis) with a mean duration of 14 years.  The finding that all patients have a 
generalized form of vitiligo in this study can be explained by the fact that children, in whom 
segmental vitiligo is a common presentation, were not included in this study.  Nevertheless, in 
comparison with the study of Handa et al., (1999) who reported 70% of patients with vitiligo 
vulgaris, 15% of patients with focal vitiligo and 15% with segmental vitiligo, the lack of cases of 
localized vitiligo is striking.  This is a significant factor as patients with segmental vitiligo have 
been reported to have a superior response to therapy (Khalid and Muftaba, 1998).  This could 
explain the relatively low percentage (27%) of patients experiencing >50% repigmentation in this 
study.    
 
Another important prognostic factor is that of the activity of the vitiligo.  This is determined by the 
progression of existing vitiligo lesions, the development of new lesions as well as by repigmentation 
within existing lesions.  In this study, it was found that 62% of patients experienced progressive 
disease while 38% classified their disease activity as stable.  It could be hypothesized that 
melanocyte survival is more unlikely in stable lesions of long duration and that these patients should 
be counseled to anticipate a poor response to treatment.  This was not found to be the case, however 
with no correlation between disease activity, melanocyte survival and thus response to therapy 












The finding in this study that 44% of patients reported concomitant auto-immune disorders is higher 
than the statistics in the literature which report that 13% of vitiligo patients have an underlying 
auto-immune diathesis.  This provided an additional rationale for the choice of topical 
corticosteroids as a treatment modality.  However, an auto-immune diathesis appears to have no 
prognostic implications in predicting treatment outcome.   
 
Despite a thorough history-taking and exploration of all epidemiological factors, the 
epidemiological profile of vitiligo patients proved unhelpful in predicting their responses to 
treatment. 
 
4.5 Practical implementation of the RT-qPCR analysis and additional prognostic indicators 
 
A summary of the tyrosinase and TRP-2 mRNA expression in vitiliginous skin lesions with their 
respective subsequent repigmentation outcomes can be seen in Table 6 below.  It can be seen that 
>50% repigmentation (a good response) was found in 3/5 patients demonstrating both tyrosinase 
and TRP-2 gene expression, in only 1/4 patients demonstrating TRP-2 gene expression alone and in 
no patients demonstrating only tyrosinase gene expression (n=3).  The presence of both tyrosinase 

























  Repigmentation 
 Gene expression Treatment Poor Average Good Excellent                          
Tyrosinase and TRP-2 (n=5) Corticosteroids  1   2  
Khellin     1   1   
TRP-2 only (n=4) Corticosteroid  2      
Khellin   1      1 
Tyrosinase only (n=3) Corticosteroids  2  1     
Khellin           
 
Table 6.  Summary of tyrosinase and TRP-2 mRNA expression as determined by RT-qPCR and the 
response to either topical corticosteroid or khellin treatment following three months of therapy. 
 
It is also significant that a good correlation can be seen between melanocyte survival and response 
to khellin therapy (R² = 0.8919 as shown in Fig. 16 Chapter 3.6) which is a mitotic and melanogenic 
agent (Carlie et al., 2003).  Out of the 4 patients using khellin who demonstrated melanocyte 
survival, a good or excellent response to treatment was seen in 2/4, an average response was seen in 
1 patient and a lack of repigmentation was seen in 1 patient.  This suggests that therapeutic 
modalities stimulating melanocyte proliferation and migration should be employed in patients 
demonstrating melanocyte survival.   
 
Conversely in the two patients using khellin therapy in whom melanocyte markers were absent, a 
poor response to therapy was seen in both. This key finding that an absence of melanocyte survival 
appears to predict a poor response to treatment is recapitulated in the overall findings:  In 7/9 
patients (78%) of patients demonstrating a lack of lesional tyrosinase or TRP-2 mRNA expression, 
there was <25% repigmentation at the conclusion of a three month treatment period.  It appears that 
these therapeutic modalities are ineffective in the absence of a melanocyte/melanoblast reservoir 
that can be stimulated.  These patients should be counseled against expensive, inconvenient 
therapies with noteworthy side effects and should rather be encouraged to use alternative options 
such as cosmetic camouflage techniques.  This would avoid the inevitable heartbreak which goes 












An important epidemiological factor to emerge from this study is the presence of a co-existing auto-
immune condition in 44% of vitiligo patients.  As corticosteroid therapy allegedly exerts its effects 
in vitiligo by means of its immunosuppressive and anti-inflammatory properties (Boumpas et al., 
1993; Ortonne, 1998) it could be hypothesized to best benefit patients with an auto-immune 
diathesis.  This reasoning seems to be flawed for our population as 100% (6/6) vitiligo patients with 
an associated auto-immune condition using corticosteroid therapy showed <25% repigmentation 
while 2/3 (66%) patients with a co-morbid auto-immune condition receiving khellin demonstrated 
>50% repigmentation.  This unexpected result is validated by the fact that overall, vitiligo patients 
showed similar response rates to both treatment modalities.  It appears that an auto-immune 
diathesis alone cannot be used as a justification in the decision to use topical corticosteroid therapy 
which should be employed only in patients with recent onset or active vitiligo where the melanocyte 
destruction stimulating this auto-immunity is ongoing.  It could be postulated that these auto-
immune mechanisms may be quiescent in stable vitiligo rendering corticosteroids a less effective 
treatment option for these patients.  New evidence is emerging that immunomodulators, in 
particular calcineurin inhibitors, can induce repigmentation in vitiligo patients through non-immune 
mechanisms, particularly in segmental vitiligo.  Recent in vitro evidence of a direct interaction 
between tacrolimus and keratinocytes creating a favourable milieu for melanocytic growth and 
migration has been reported (Lan CC et al., 2005; Kang and Choi 2006).  Tacrolimus-treated 
keratinocyte supernatants resulted in melanoblast and melanocyte proliferation as well as enhanced 
stem cell factor and metalloproteinase-9 activity which is involved in cell migration.  It is possible 
that corticosteroids also have non-immune targets in the treatment of vitiligo and perhaps, should 
not be utilized only in the setting of patients with an autoimmune diathesis, active vitiligo or micro-
inflammatory vitiligo.  Further large-scale epidemiological studies evaluating the clinical settings in 
which corticosteroid therapy would be most appropriate need to be conducted.  Studies elucidating 
the predominant mechanism of corticosteroids in vitiligo – immune vs non-immune- are also 
needed.  Until such time, logic dictates that corticosteroids should have superior efficacy in patients 
where immune mechanisms are at play. 
  
The epidemiological profile of each vitiligo patient in combination with the results of the RT-qPCR 
analysis of their lesional skin biopsy samples, can therefore be used to plan an individualised 
therapeutic approach as is shown in Figure 26.  This algorithm should apply only to the 











vitiligo is a micro-inflammatory disease.  Micro-inflammatory vitiligo is recognized clinically by 
depigmented patches surrounded by a raised erythematous border with variable scale and marginal 
hyperpigmentation and histologically by a superficial perivascular lymphohistiocytic infiltrate and 
variable vacuolar change, lichenoid inflammation, epidermal spongiosis and psoriasiform epidermal 
hyperplasia.  Lichenoid infiltrates have also been demonstrated in 23% of common macular vitiligo 
lesions where the inflammation was subclinical.  Therapeutic modalities for vitiligo should 
therefore take this stage into account more specifically (Swick and Walling, 2008; Attili and Attili, 
2008).” 
 
Positive tyrosinase and/or TRP-2 mRNA expression shown during molecular profiling of vitiligo 
lesions by RT-qPCR indicates a melanocyte/melanoblast reservoir.  Should these patients have no 
history of an auto-immune diathesis and should they have stable disease (as defined in Chapter 2.6), 
they would benefit best from topical khellin therapy in combination with daily sunlight exposure in 
order to stimulate melanogenesis.  It would appear that topical corticosteroids would not provide 
any additional benefit in this patient group.  The presence of an auto-immune diathesis, 
inflammatory vitiligo or active disease, however, suggests that the auto-immune mechanisms 
hypothesized to initiate/propogate the disease process, are still active.  In these patients, the topical 
khellin and sunlight therapy should be used in combination with topical corticosteroids to dampen 
down the ongoing immune response targeting the melanocytes while simultaneously stimulating 
melanogenesis.  Should these therapies have failed following a three month trial period, 
dermatologists, knowing the heterogenous response of vitiligo patients to various therapeutic 
modalities, should persevere in exploring alternative therapeutic options. 
 
In the absence of a melanocyte/melanoblasts reservoir, as indicated by the RT-qPCR analysis of 
lesional skin samples, khellin should not be prescribed.  The chance of repigmentation is poor in 
this patient group.  Patients should be counseled and alternative treatments such as camouflage 
cosmetics or surgical treatment modalities should be advocated.  However, in the presence of an 
auto-immune diathesis, inflammatory vitiligo or active disease, topical corticosteroid therapy should 














Fig. 26   Proposed algorithm of management of vitiligo patients based on their epidemiological 
profile and results of the molecular profiling of their vitiligo lesions by means of RT-qPCR 
 
 
4.6 Future endeavours 
 
Although the evidence presented in this study gives clear priorities for research, it is not robust 
enough to provide comprehensible guidelines in terms of the prognosis or treatment of vitiligo 
patients.  The algorithm presented in Fig. 26 above on the management of vitiligo patients based on 
their epidemiological profile and the molecular profile of their lesional skin will need further fine-
tuning.  This would depend on an expanded dataset with an increase in the sample size as well as a 
more exacting study design.  Inclusion of patients with segmental vitiligo, stringent selection of 
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biopsies from only areas to be treated and a longer study period of one year to allow for trials of 
different therapeutic modalities would provide more meaningful results. 
 
Pigment cell research is experiencing an exciting era with new innovations in stem cell biology.  
Novel cell surface markers have been identified on human follicular bulge cells using microarray 
analyses and precise laser capture microdissection (Osawa et al., 2005) and the presence of 
intraepidermal stem cells has been confirmed (Passeron et al., 2007).  The ability to differentiate 
between epidermal and follicular melanocyte stem cells could provide the key to profiling vitiligo 
lesions.  Passeron et al., (2007) explored the antigenic expression patterns of markers for the 
subpopulations of melanocytes in the epidermis and hair follicles.  This study demonstrated that 
while tyrosinase and TRP-2 were positive markers for melanocytes/melanoblasts in the epidermis, 
Pmel17, c-KIT and Bcl-2 could prove to be superior markers of melanocyte stem cells in the bulge 
region of the hair follicle.  Analysing vitiligo lesions more widely to include these markers would 
provide further insight into the targets of current vitiligo therapies.   
 
4.7 Concluding remarks 
 
This study has provided new insights into the fate of melanocytes in vitiligo.  The fact that there is 
melanocyte survival in 60% of vitiligo patients has important therapeutic implications, providing 
greater motivation to persevere with treatment in these patients.  A prognostic test would enable 
physicians to develop practical management plans and offer some guidance in a condition whose 
treatment is otherwise rather hit-or-miss.  Despite the limitations of this study which have been 
outlined in 4.2 above, the molecular profile of vitiligo lesions can still be used as a presumptive 
prognostic aid.  Evidence of melanocyte survival should encourage physicians to instigate treatment 
– in particular melanogenic agents such as KUVA.  It would also encourage perseverence with 
alternative therapeutic options should a lack of repigmentation be observed with one therapy.  An 
absence of melanocyte markers, however, is a poor prognostic sign and medical therapy should be 
cautioned against.  In these cases, melanocyte grafting techniques or camouflage cosmetics should 
be considered depending on the extent and stability of the patients’ lesions as well as their level of 
distress.  The epidemiological profile can also guide dermatologists in planning treatment for their 
vitiligo patients.  A history of an auto-immune diathesis, inflammatory vitiligo or of an active 












Despite the despondency and frustrations implicit in this condition, physicians should not fall into 
the trap of dismissing vitiligo as a condition not worth treating.  Instead, a drive to invest more 
research into the nature of this disorder and its treatment and to provide more tangible links between 
























Consent form for punch biopsies 
 
To be filed in the patients folder              Patient code number…………. 
 
I (full name)……………………………………………………………………………… 
hereby give consent for a punch biopsy to be taken from my skin. I understand that the 
doctor/clinician will remove a very small (4mm) piece of my skin from the pigmented skin and 
from the vitiligo skin and that the risk of infection is minimal.  This procedure will be performed 
under local anaesthesia. 
 
I understand that my participation in this study is absolutely voluntary and that should I refuse to 
participate or decide to withdraw from participation at any time, it will not affect my subsequent 
clinical treatment or care.  
 
I hereby understand that my skin will be used in scientific experiments to improve our knowledge 
about whether any pigment cells that cause colour in the skin survive in vitiligo and whether their 
survival affects response to treatment.  
I understand that any results obtained will be entirely confidential. 
I understand that I may be contacted in the future for consent for further studies on these skin 
samples should : 
1) my skin yield results that may impact on potential treatment for me, or 
2) should there be a need to use these biopsies for other studies. 
 
I consent/do not consent for photographs of my skin to be taken for the purposes of this study.  I 
understand that it will not be possible to identify me from these photographs. 
 






Groote Schuur Hospital folder number:……………………………………………………. 
 
 
Doctors Full name:……………………………….......................Doctors Signature…………… 
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